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1. Introduction 
 
1.1. Ephrin binding receptors (Eph) 
 
Ephrin binding receptors comprise the largest subfamily of receptor protein 
tyrosine kinases. This subfamily consists of 14 members and is divided into two 
groups based on the similarity of their extracellular domain sequences and their 
affinities for binding ephrin-A or ephrin-B ligands. According to the Eph Nomenclature 
Committee (1997) Eph receptors interacting preferentially with ephrin-A proteins are 
called EphA and Eph receptors interacting preferentially with ephrin-B proteins are 
called EphB. Mammals have nine A-subclass Eph-receptors (EphA1 to EphA9) and 
five B-subclass Eph-receptors (EphB1 to EphB5) (Yamaguchi and Pasquale, 2004). 
The Eph receptor family plays an important role in tissue development including 
neuronal and vascular networks during embryogenesis. The functions of Eph 
receptors in the adult brain have only recently been investigated. Y. Yamaguchi and 
E. Pasquale (2004) have shown that the Eph receptors regulate the structure and 
physiological function of excitatory synapses and might play a significant role in 
higher brain functions. It was shown that the Eph receptors and their ephrin ligands 
play a critical role in modulating multiple aspects of synaptic structure and 
physiology. Historically, these proteins have been best known for their role in axon 
guidance during the assembly of neural network (Wilkinson, 2001).  
Binding of Eph receptors to their ligands induces receptor dimerization and 
subsequent trans-phosphorylation by the cytoplasmic kinase domains of the two 
receptors. Multiple tyrosine residues important for autophosphorylation and 
recruitment of adaptor proteins have been mapped to the juxtamembrane and kinase 
domains of the receptor. 
To convert Eph receptors into the autoinhibited inactive state, their juxtamembrane 
tyrosine residues need to be dephosphorylated by a phosphotyrosine-specific protein 
phosphatase (PTP). Recent work identified protein-tyrosine phosphatase receptor 
type O (Ptpro) as a specific PTP that efficiently dephosphorylates EphA and EphB 
receptors (Shintani et al., 2006). 
Many of the proteins identified in the Eph signalling pathways have been 
implicated in regulating cell morphology, attachment and motility. For example, Eph 
receptors are found to regulate integrin-dependent cell adhesion through activation of 
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c-Jun kinase via Nck-interacting Ste20 kinase in endothelial and neuronal cells 
(Becker et al., 2000; Huyn-Do et al., 1999). In addition, focal adhesion kinase (FAK) 
was implicated in the regulation of cell adhesion in prostate carcinoma PC-3 cells 
(Cheng et al., 2002). Eph receptor signalling also regulates actin dynamics via small 
GTPases of the Rho family. Taken together, these studies demonstrated the role of 
Eph receptor signalling in changing of cellular morphology and architecture, cell 
attachment and cell motility. 
 
1.2. Ephrins 
 
The ligands for Eph receptors have been named ephrins (Eph Nomenclature 
Committee, 1997). Based on their structures and sequence relationships, human 
ephrins are divided into the ephrin-A class, containing three proteins, which are 
anchored to the membrane by a glycosylphosphatidyl-inositol (GPI) linkage, and the 
ephrin-B class, containing five proteins, which are transmembrane proteins. Analyses 
of amino acid sequences of ephrin ligands indicate that each ligand consists of a 
signal peptide at the amino terminus, followed by a conserved receptor binding 
region containing conserved cysteine residues and a spacer region. At the carboxy 
terminus, the class A ligands contain a hydrophobic region comprising the GPI 
linkage. Ephrin-B ligands contain a transmembrane domain and a cytoplasmic 
domain containing PDZ-binding motif and conserved tyrosine residues that may be 
phosphorylated and serve as docking sites for proteins containing SH2/SH3 domains. 
Mostly ephrin-As bind to EphA receptors and ephrin-Bs bind to EphB receptors. But 
there are exceptions: most notable are ephrin-A5 that can bind to EphB2 receptor 
and ephrin-B1 that can bind to EphA4 receptor (reviewed in Kullander and Klein, 
2004). 
The cytoplasmic and transmembrane domains of ephrin-B ligands are analogous 
to those of conventional receptor molecules. Ephrin-B ligands share a single 
transmembrane domain, a cytoplasmic region, and a C-terminal PDZ binding motif. 
The cytoplasmic domains of ephrin-B ligands become phosphorylated on tyrosine 
residues following receptor binding (Brückner et al., 1998; Holland et al., 1996). PDZ 
domain-containing proteins, including Syntenin, Grip, Pick 1, Phip, the 
phosphotyrosine phosphatase FAP-1 were shown to interact with ephrin-B ligands 
(Lin et al., 1999; Torres et al., 1998), and PDZ-RGS, a PDZ containing protein with 
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GTPase stimulating activity, which regulates SDF-1 induced chemoattraction (Lu et 
al., 2001). Despite lacking a cytoplasmic domain, ephrin-A ligands also appear to be 
capable of signal transduction. There are precedents for GPI anchored proteins to 
signal, and a number of such proteins are involved in immune responses (Ropert and 
Gazzinelli, 2000). Recent data have shown that signalling through ephrin-A ligands 
may be mediated by the recruitment of adapter proteins. The ephrin-A ligands have 
been localized to lipid microdomains or rafts, which contain other signalling 
molecules such as G proteins and caveolin proteins, indicating ephrin-A ligands may 
activate a number of signalling pathways (Oh and Schnitzer, 2001). Stimulation of 
ephrin-A8 by EphA5–Fc has been shown to recruit and activate Fyn, a member of the 
Src kinase family. Fyn, in turn, activates p80 kinase to induce cytoskeletal changes in 
fibroblasts and increase cell adhesion to fibronectin through increasing the number of 
focal adhesions (Davy et al., 1999). Ephrin-A2 and ephrin-A5 have also been 
localized to lipid microdomains in HEK293 transfected cells. These observations 
indicate that ephrin-A ligands are capable of transducing signals to influence actin 
cytoskeletal changes, attachment, and migration. 
Functional evidence of bi-directional signalling came from studies in zebrafish and 
homozygous null mice. Mellitzer et al. (1999) developed a zebrafish animal cap 
assay to study cell intermingling between two populations of cell expressing either 
Eph receptor or ephrin ligand. Juxtaposition of these two populations of cell leads to 
restriction of cell intermingling and establishment of boundary. However, expression 
of truncated forms of either EphB2 or ephrin-B2 lacking cytoplasmic domains in the 
animal cap results in cell intermingling across the border, indicating that signalling 
pathways directing cellular repulsion are activated through the ligand as well as the 
receptor. The functional role of ephrin cytoplasmic domain is demonstrated in ephrin-
B2∆C/∆C mice expressing a mutant ephrin-B2 with cytoplasmic domain deletion 
(Adams et al., 2001). These mice exhibit vascular remodeling defects that are 
reminiscent of one subset of the phenotypes in ephrin-B2-/- null mice, indicating that 
the signalling through ephrin-B2 is required for vascular development. Interestingly, 
unlike ephrin-B2-/- null mice, no defects in neural crest cell migration are present in 
ephrin-B2∆C/∆C mice. These results indicate that ephrin-B2 signalling is required for 
vascular development, but is dispensable for neural crest cell migration during 
embryogenesis. 
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1.3. Eph–ephrin signalling system 
 
In each subclass, A or B, receptor–ligand binding is promiscuous. With few 
exceptions, one ligand is able to bind to multiple receptors; and conversely, one 
receptor can bind to multiple ligands within the same subclass (Gale et al., 1996). 
Thus, the specificity of ligand–receptor interaction apparently comes from the cell-
specific localization of these molecules in vivo. All other RTKs bind to soluble ligands, 
which can diffuse considerable distances, but ephrins require membrane attachment 
for proper functioning, limiting the action of this system to cell-to-cell communication. 
Another unique aspect of the ligand–receptor interaction in the Eph family is that the 
extent of receptor activation is dependent on the oligomerization state of the ligands. 
Soluble ephrin–Fc fusion proteins require preclustering (with anti-Fc antibodies) into 
aggregates to induce robust Eph phosphorylation and biological responses (Davis et 
al., 1994), whereas nonclustered forms can act as functional antagonists (Gerlai et 
al., 1999). The regulation of Eph–ephrin clustering under physiological conditions is 
not understood. Experiments with ephrin-A5-coated beads performed by Wimmer-
Kleikamp et al (2004) suggested that ephrins induce Eph clustering, but that cluster 
growth occurs independently of ephrin contacts and involves direct Eph–Eph 
interactions. 
Crystallographic studies indicate that binding of ephrins to Eph receptors is 
achieved by the formation of tetrameric structure comprising two receptor molecules 
and two ligand molecules (Himanen et al., 2001; Nikolov et al. 2005). The Eph–
ephrin binding and the formation of tetrameric structure lead to conformational 
alterations in the B-class ephrin transmembrane and cytoplasmic domains. This 
could result in a more permissive conformation that allows phosphorylation of the 
ephrin cytoplasmic tail by adjacent Src family tyrosine kinases (SFKs) that are also 
localized in lipid rafts (Cowan C. and Henkemeyer M., 2002). The effects on receptor 
phosphorylation and activation of downstream signalling pathways differ when 
soluble recombinant ephrin ligands are presented to receptor either as ephrin–Fc 
dimers, or as clustered multimers. Both A and B class ephrins are capable of 
inducing signal transduction cascades upon binding Eph receptors. Following ephrin 
binding to its receptor, in addition to stimulating signalling cascades within the Eph-
bearing cell (referred to as “forward signalling”), ephrins can elicit signals within the 
ephrin-bearing cell (“reverse” signalling). Both signalling events can happen 
 8
simultaneously, and the relative contributions of Eph forward and ephrin reverse 
signalling can vary depending on cellular context. Signalling events activated by Eph 
forward and ephrin reverse signalling are beginning to be characterized, and seem to 
be different from canonical RTK signalling that largely makes use of Ras–MAPK 
(mitogen-activated protein kinase) and phosphatidylinositol 3-kinase (PI3K)–Akt 
pathways (Eswarakumar et al. 2005). Ephs are poor activators of Ras–MAPK and 
PI3K–Akt pathways and, instead, recruit phosphotyrosine-binding adaptor proteins to 
activate Rho GTPases and remodel the actin cytoskeleton (Noren and Pasquale, 
2004). Ephrin-B reverse signalling also activates Rho GTPases (involving Src family 
tyrosine kinases rather than using an intrinsic kinase domain) and uses 
phosphotyrosine-independent docking mechanisms (Cowan and Henkemeyer, 2001; 
Palmer et al., 2002). 
Taken together, these findings suggest that Eph signalling requires a lot of factors 
in order to achieve precise in vivo regulation of the multiple functions, from embryonic 
patterning, neuronal targeting, to angiogenesis. 
 
1.4. Ephrin-B1 and EphB2 
 
EFNB1 and EPHB2 are expressed throughout most tissues in vertebrate embryos. 
Together with the EphB2-receptor ephrin-B1 forms a signalling complex. Both ephrin-
B1 and EphB2 can act as ligand and receptor (Schmucker and Zipursky, 2001; 
Cowan and Henkemeyer, 2002) as it was mentioned before. Therefore, EphB2–
ephrin-B1 can act in a bi-directional signalling pathway (Fig. 1). Eph-receptors are 
activated when they are bound by clustered membrane-attached ephrin-ligands. 
Therefore, close contact between cells expressing Eph-receptors and ephrins is 
essential for receptor activation. By contrast, high-affinity interactions between 
ephrins and Ephs usually result in contact-mediated repulsion. Possible solutions to 
this paradox are ectodomain cleavage and endocytosis. Axon repulsion by ephrin-B1 
requires cleavage of the ephrin-B1 ectodomain by γ-secretase in a presilin-
dependent way (Tomita et al., 2006). This secretase was shown to associate with 
ephrin-B1 before cell–cell contact. Cleavage of the ephrin ectodomain by γ-secretase 
occurred in cis (with both proteins present in the same membrane) and proceeds 
independently from the ephrin-B1 – EphB complex formation. In it’s turn, the C-
terminus of ephrin-B1 regulates the exocytosis of matrix metalloprotease-8 (MMP-8), 
 9
a key protease of ephrin-B1 cleavage, in response to the interaction with EphB2 
receptor (Tanaka et al., 2007). This group also showed that EphB2 – ephrin-B1 
interaction promoted secretion of MMP-8 without increasing the expression level of 
MMP-8, proposing that ephrin-B1 signalling resulted in increased transport of MMP-8 
from the cytoplasm to the cell surface (Tamaki and Yamashina, 2002). 
 
 
 
 
A mechanism that specifically removes Eph–ephrin complexes from the cell 
surface and enables the detachment of cells is rapid internalisation (trans-
endocytosis). In cell culture assays, the interaction of cells expressing EphB 
receptors with cells expressing ephrin-B1 results in the rapid formation of intracellular 
vesicles containing EphB–ephrin-B complexes in both cell populations (Zimmer et al., 
2003). The balance between reverse, forward or bi-directional endocytosis might 
depend largely on the cellular context, but is also regulated by the intracellular 
 10
domains of the proteins: when an EphB2-expressing cell contacted a cell expressing 
a C-terminally truncated version of ephrin-B1, endocytosis of the complex was 
favoured into the EphB2-expressing cell. When cells expressing C-terminally 
truncated versions of EphB2 and ephrin-B1 interacted, neither of the two proteins 
was endocytosed and cells adhered for prolonged periods of time. When neurons 
expressing ephrin-B1 were confronted with a cell expressing a C-terminally truncated 
version of EphB2 (and, thereby, incapable of eliciting EphB2 endocytosis), they 
displayed slower detachment than neurons confronted with a cell expressing full-
length EphB2 (Zimmer et al., 2003). In endothelial cells, internalisation of receptor–
ligand complexes and cell retraction depend on actin polymerisation and Rac activity 
within the Eph-expressing cells (Marston et al., 2003). Cowan et al. (2005) have 
implicated the Rac exchange factor Vav in EphB-mediated endocytosis. It was 
suggested that trans-endocytosis of ephrin-Bs depends on a clathrin-mediated 
pathway and proceeds mainly through the EphB-receptors internalisation (Parker et 
al., 2004). 
Eph-ephrin binding autophosphorylates several tyrosine residues in the 
intracellular part of the receptors. EphB2-receptor, which has a strongest affinity to 
ephrin-B1, comprises a kinase domain and a juxtamembrane domain. After 
juxtamembrane tyrosine residues are phosphorylated, this domain is released from 
the interaction with the kinase domain, allowing the kinase domain to convert into its 
active state (reviewed in Kullander and Klein, 2002). Eph receptors transduce 
forward signals into the cell through activation of their intracellular catalytic tyrosine 
kinase domain. 
In contrast, ephrins do not have an intracellular kinase domain and must therefore 
transduce their reverse signals in a different way. Reverse signalling may be 
enhanced by the ability of the Eph–ephrin tetramers to aggregate into higher-order 
clusters within the lipid rafts, which leads to the formation of discrete signalling 
centres. The cytoplasmic tail of ephrin-B1 contains several very conserved amino 
acids, including six phosphorylated tyrosines corresponding to Tyr313, Tyr317, 
Tyr324, Tyr329, Tyr343 and Tyr344 in human ephrin-B1 protein (Fig. 1). These 
tyrosines become phosphorylated after the engagement with the cognate EphB 
receptors, four of them (Tyr313-Tyr329) are the main targets of claudin4-iduced 
phosphorylation (Tanaka et al., 2005). Tyr313 is involved in STAT3 – ephrin-B1 
interaction (Bong et al., 2007); Tyr317 forms a domain YEKV for Grb4 docking (Bong 
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et al., 2004; Su et al., 2004). Tyr324 was shown to be important for EphB2 – ephrin-
B1 reverse signalling (Kalo et al., 2001), however, function of this tyrosine is still not 
clear. Tyr329 is involved in STAT3 – ephrin-B1 interaction (Bong et al., 2007) and 
Par-6 – ephrin-B1 binding (Lee et al., 2008). Tyr343 forms clathrin endocytosis signal 
motif – YXXφ (Bonifacino and Trub, 2003; Parker et al., 2004). Tyr344 is a part of 
PDZ-binding domain (YKV). Like cytokine receptor signalling, the phosphorylation of 
B-ephrin cytoplasmic tyrosines is thought to be important in the transduction of 
reverse signals (Cowan and Henkemeyer, 2002). It was shown by Brückner et al. 
(1997) that in fibroblasts ephrin-B1 phosphorylation is initiated by platelet-derived 
growth factor (PDGF) in cis. Palmer et al. (2002) identified Src family kinases (SFKs) 
and the PDZ domain-containing phosphatase PTP-BL as regulators of further ephrin-
B1 phosphorylation and reverse signalling in fibroblasts. Tyrosinephosphorylated 
ephrin-B1 molecules recruit the adaptor protein Grb4 (growth-factor-receptor-bound 
protein 4), which consists of one SH2 and three SH3 domains and can increase FAK 
(focal adhesion kinase) catalytic activity as well as cell rounding (Cowan and 
Henkemeyer, 2001). Binding of Grb4 to ephrin-B1 requires 22 amino acids of the 
cytoplasmic region, which is identical between ephrin-B1 and ephrin-B2 and contains 
three of the six conserved tyrosine residues. An NMR binding study identified two 
tyrosine residues, corresponding to Tyr 313 and Tyr 329, within the 22-residue 
hairpin of ephrin-B1 as phosphorylation sites that may be relevant for high-affinity 
binding to the Grb4 SH2 domain (Song, 2003). However, the critical tyrosine residue 
involved in the binding of Grb4 SH2 domain is not yet clear. Bong et al., (2004) show 
that an FGFR can induce the phosphorylation of ephrin-B1 and promote the 
formation of a complex between ephrin-B1 and Grb4. This group also define the 
critical region within ephrin-B1 required for binding Grb4 and identify Tyr-298 
(corresponding to 313 in human ephrin-B1) as vital for binding the Grb4 SH2 domain 
in vivo. They suggest that ephrin-B1 reverse signalling may be modulated by FGF 
(fibroblast growth factor) signalling and that the Grb4 adaptor protein may participate 
in this signalling as a result of being recruited to the phosphorylated Tyr 298 site. 
Claudins are tetraspan transmembrane proteins comprising a multi-gene family 
with more than 20 members, and creating a complex with ZO-1, ZO-2 and ZO-3, 
which represent plaque structures underlying plasma membranes (Itoh et al, 1999; 
Tsukita et al, 2001). Although ephrin-B1 interacts with claudins on the same epithelial 
cell surface in cis, the tyrosine phosphorylation of the cytoplasmic region of ephrin-B1 
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was found to be markedly enhanced by the cell–cell contact formation in a manner 
dependent on claudin (Tanaka et al., 2005). This group also has shown that ephrin-
B1 and claudin associate only in cis, in the same membrane, but not in trans, in 
opposing membranes. Par-6 is a major scaffolding protein that constitutively binds 
atypical protein kinase C (aPKC) through its PB1 (Phox and Bem 1) domain; binding 
stimulates a conformational change in an active Cdc42-GTP, causing aPKC 
activation in epithelial cells (Joberty et al., 2000). Lee et all (2008) present evidence 
that Par-6 has a crucial role in the ability of ephrin-B1 to regulate tight junction 
formation. Par-6 is a member of Par polarity complex, the localized activity of this 
complex (Par-6/aPKC/Cdc42-GTP) to the apical cell junctions regulates tight junction 
formation, and tight junction complexes are associated with the actin cytoskeleton, 
which is reorganized for the formation and maintenance of cell–cell contacts (Lee et 
al., 2008). Ephrin-B1 competes with Cdc42 for association with Par-6. This 
competition leads to the inactivation of Par complex and loss of tight junction. 
Interaction between ephrin-B1 and Par-6 is disrupted by tyrosine phosphorylation of 
the intracellular domain of ephrin-B1. Lee et al. (2008) expect this to be a mechanism 
by which ephrin-B1 signalling regulates cell–cell junctions in epithelial cells. They 
also showed that the most crucial tyrosine in Par-6 – ephrin-B1 interaction 
corresponds to Tyr 329 in human ephrin-B1 protein. 
Palmer et al. (2002) showed that in primary endothelial cells SFKs are activated 
upon binding to ephrin-B1 ligands and are required for ephrin-B1 tyrosine 
phosphorylation and ephrin-B1-mediated angiogenic sprouting of the cells, however, 
SFKs are not required for all angiogenic stimuli. The responses of endothelial cells to 
other potent angiogenic factors such as the chemokine SDF-1, via its receptor 
CXCR4, and Ang-1, via its receptor Tie-2, were not affected by inhibition of SFKs 
(Palmer et al., 2002). Although SFKs are rapidly and stably recruited to ephrin-B1-
containing membrane clusters, their activation is transient. 
In PC-3 cells, ephrin-B1 ligands recruit PTP-BL to the membrane via PDZ domain 
interactions and become dephosphorylated. PTP-BL contains five PDZ domains, 
which interact with other cytoplasmic proteins including a GTPase-activating protein 
(GAP) with specificity for the Ras-like GTPase Rho (Saras et al., 1997). 
Chong et al., (2000) demonstrate that FGF receptor activation inhibits x-ephrin B1-
induced cell dissociation in Xenopus embryos. They show that the fibroblast growth 
factor (FGF) receptor associates with and induces the phosphorylation of x-ephrin-
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B1. This group also define critical residues within a conserved region of the 
intracellular domain necessary for this interaction. These results prove a functional 
and physical interaction between the FGF tyrosine kinase family of receptors and the 
ephrin-B1 ligand and implicate their cross talk in regulating adhesion. 
Ephrin-B1 protein is located in lipid rafts (Brückner et al., 1999), however, raft 
disruption by cholesterol depletion in NIH3T3-sites in ephrin-B1 cells does not affect 
the clustering of ephrin-B1 induced by the receptor and the subsequent recruitment 
of Src into these clusters (Palmer et al., 2002). Lipid rafts are small (<100 nm) 
membrane domains (Friedrichson and Kurzchalia, 1998; Varma and Mayor, 1998), 
rich in sphingolipids and cholesterol. Lipid rafts can incorporate GPI-anchored 
proteins, specific transmembrane proteins, and doubly acylated proteins like tyrosine 
kinases of the Src family (Simons and Ikonen, 1997). Rafts function as platforms for 
the assembly of cytoplasmic and membranous signalling molecules and for polarized 
membrane traffic (Holowka and Baird, 1996; Simons and Ikonen, 1997). In the 
signalling of membrane receptors, adaptor proteins provide docking sites for 
downstream enzymes in proximity to the activated receptor. In HEK 293 cells 
Brückner et al. (1999) describe the interaction of ephrin-B1 with the multi-PDZ 
domain protein glutamate receptor–interacting protein (GRIP), a protein, termed 
GRIP2 that contains seven PDZ domains (PDZ1-7). Ephrin-B1 is associated with 
sphingolipid/cholesterol-rich raft membrane microdomains and recruits a significant 
fraction of GRIP proteins from the cytoplasm into these rafts. Stimulation with EphB2 
receptors reorganizes ephrin-B1-containing rafts into larger raft patches that 
concentrate GRIP proteins on the cell surface. 
To transduce reverse signals, ephrin-B1 cytoplasmic tails associate with other 
cytoplasmic proteins. They appear to be proteins containing PDZ (postsynaptic 
density-95, disclarge and zonulin-1 proteins) domains, such as PDZ-RGS3 protein, 
which have been shown to bind to the carboxyl termini of the ephrins of B-class 
(YKV). At least one protein containing a Src homology 2 (SH2) domain, Grb4, is 
recruited to these ephrins cytoplasmic tails in a phosphotyrosine-dependent manner. 
Both types of ephrin-interacting protein have been reported to direct signals that 
regulate cytoskeletal dynamics (Cowan and Henkemeyer, 2002). In neurons, ephrin-
B1 reverse signals promote the maturation of spines through a signalling pathway 
involving Grb4, G protein-coupled receptor kinase-interacting protein (GIT1) and the 
exchange factor for Rac GTPase, β-PIX (Segura et al., 2007). The activation of Src 
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kinases involves metalloproteinase and presenilin-1–γ-secretase cleavage of ephrin-
B1, producing an intracellular peptide that binds to and activates Src by inhibiting its 
association with the inhibitory kinase Csk (Tomita et al., 2006). This process occurs 
independently from the ligand-receptor binding. 
The signalling pathway downstream of ephrin-B1 involves Dishevelled (Dsh), 
which binds either directly to the cytoplasmic tail of ephrin-B1, or indirectly through 
interaction with Grb4 (Tanaka et al., 2003). Dishevelled (Dsh) is a cytoplasmic protein 
containing three conserved protein domains: DIX (Dishevelled-Axin), PDZ and DEP. 
Dsh is known to be located as a downstream molecule of Frizzled (Frz) and involved 
in at least two independent signalling pathways in Drosophila, Xenopus and 
zebrafish. One pathway is a canonical cascade that leads to the dorsalization and 
determination of the body axis by interacting with β-catenin and the other is a planar 
cell polarity (PCP) cascade (Tanaka et al., 2003). 
Previously, it was reported by Bong et al. (2007) that STAT3 is important for 
ephrin-B1 signalling. Among the six tyrosine residues present in the intracellular 
domain of ephrin-B1 (see above), one resides in a well conserved YXXQ motif at the 
C-terminus and is rapidly phosphorylated upon engagement of the EphB ectodomain 
(Kalo et al., 2001) or in response to FGF receptor activation (Cong et al., 2000, Bong 
et al., 2004). STAT3 plays pivotal roles in development, proliferation, apoptosis and 
tumorigenesis. STAT3 is activated in response to several agents, including growth 
factors, cytokines, and oncoproteins (Bong et al., 2007). The activated STAT3, 
dimerizes, translocates to the nucleus, recognizes target DNA, and induces gene 
expression (Taga and Kishimoto, 1997). 
Twist1, a highly conserved basic helix-loop-helix transcriptional factor, was 
previously shown to play a pivotal role in mesodermal, myoblast, and osteoblast 
differentiation (Bialek et al., 2004; Baylies and Bate, 1996; Castanon et al., 2001). 
Mutational inactivation of the Twist1 gene resulted in Saethre-Chotzen syndrome 
(OMIM 101400), an autosomal dominant disorder characterized by premature fusion 
of the cranial sutures, skull deformations, limb abnormalities, and facial 
dysmorphisims (El Ghouzzi et al., 1997, Howard et al., 1997). Cheng et al. (2008) 
detected an elevated level of activated STAT3 in the highly invasive colon carcinoma 
cells and demonstrated its role in transcriptional regulation of Twist1. This group 
showed that STAT3 bound to the Twist1 promoter and activated its transcriptional 
activity. They also demonstrate that TWIST1 is a transcriptional target of STAT3. 
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Contractor et al. (2002) show that dimeric EphB-Fc fusion proteins can directly 
activate presynaptic ephrin-B1 ligands and potentiate mossy fiber synaptic 
transmission, thus occluding subsequent tetanus-induced LTP (long terminus 
potential) in neurons. 
In summary, ephrin-B1 and EphB2 are involved in processes of cell adhesion and 
cell migration (Böhme et al., 1996). Therefore, this signalling system plays an 
important role in embryonic morphogenesis including definition of tissue borders and 
segmentation. So far, analysis of Eph/ephrin system focused on its significance for 
skeletal development, angiogenesis and plasticity of the nervous system. Ephrin-B1 
plays an important role for axon guidance and plasticity of neurons. Ephrins form a 
high-affinity multivalent complex with their receptors present on axons. After 
Eph/ephrin engagement axons can be rapidly repelled (Murai and Pasquale, 2003). 
Furthermore, ephrin-B1 is involved in other processes such as cancerogenesis. 
 
1.5. Ephrin – Eph signalling in vascular and nervous systems 
 
Lim et al. (2008) examined the regulatory function of ephrin-B reverse signalling 
on synapse development soon after the establishment of retinotectal projections in 
the Xenopus tadpole. Using in vivo timelapsed imaging of developing RGC axons in 
the tectum, they found that acute elevation of ephrin-B signalling accelerates 
presynaptic maturation without affecting the overall axonal growth. Functional 
synaptic maturation was facilitated by ephrin-B signalling in two apparent phases: an 
early phase of presynaptic enhancement of transmitter release and a late phase of 
postsynaptic increase in the glutamate responsiveness, both of which contribute to 
an elevated AMPAR-mediated synaptic transmission. 
EphB1 is largely confined to the nervous system, and ephrin-B3 and EphB2 are 
expressed in neuroectoderm and heart (Henkemeyer et al. 1996). Previous studies 
on Efnb3-/- gene deletion (Rodenas-Ruano et al., 2006) and hippocampusspecific 
Efnb2-/- conditional deletion (Grunwald et al., 2004) in mice showed no structural 
alteration in synaptic morphology in the hippocampus, although the level of synaptic 
proteins was altered in Efnb3-/- mice (Rodenas-Ruano et al., 2006). 
Eph–ephrin signalling has also been implicated in trans-endocytosis events at the 
neuron-to-glia interface. Using time-lapse microscopy, it was shown that hippocampal 
neurons exogenously expressing EphB2 receptors release or pinch-off EphB2-
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containing vesicles from the neuron at sites of neuron-to-glia contact. These findings 
suggest that Eph–ephrin signalling is involved in the glial cell-mediated fine sculpting 
of neuronal structures (Lauterbach and Klein, 2006). 
EphB forward signalling might not always be linked to EphB endocytosis, but might 
modulate the endocytosis of other transmembrane proteins. In cultured hippocampal 
neurons, EphB receptors regulate clathrin-mediated endocytosis of α-amino-3-
hydroxy-5-methyl-4-isoxazolpropionic acid (AMPA)-type glutamate receptors, a 
mechanism implicated in long-term synaptic plasticity (Irie et al., 2005). These 
authors identified synaptojanin-1, a phosphatidylinositol 5’-phosphatase that is 
involved in clathrin-mediated endocytosis, as a physiological substrate for EphB2. 
Because synaptojanin-1 tyrosine phosphorylation was crucial for its role in AMPA 
receptor endocytosis, this work highlighted the importance of tyrosine kinase 
signalling in this process. 
As cell surface bound molecules, Eph and ephrin signalling mediates cell-to-cell 
contacts. During neural development, Eph receptors and ligands often display 
reciprocal expression patterns on adjacent tissue compartments such as between 
neighbouring rhombomere segments or between projecting axons and their targets. 
Bi-directional signalling of Eph receptors and ephrin ligands mediates cell–cell 
repulsion to establish rhombomere boundaries and to guide axons to their targets 
(Flanagan and Vanderhaeghen P., 1998; Klein, 2001). In addition to mediating 
cellular repulsive signals, interaction of two cell populations expressing either EphB 
receptors or ephrin-B ligand reduces the number of gap junctions between these two 
populations of cells, preventing the communication of these two groups of cells 
(Mellizer et al., 1999). 
The family of Eph receptor tyrosine kinases and their ephrin ligands play important 
roles in a variety of processes during embryonic development of mammals, lower 
vertebrates, and invertebrates such as Caenorhabditis elegans (Adams et al., 1999). 
They regulate topographic map formation in the retinotectal/retinocollicular system 
(Cheng et al. 1995; Drescher et al. 1995; Nakamoto et al. 1996; Frisen et al. 1998) 
and play essential roles in the formation and fasciculation of brain commissures 
(Henkemeyer et al. 1996; Orioli et al. 1996; Park et al. 1997). They have additional 
important functions in patterning of embryonic structures of the brain (Xu et al. 1995) 
and somites (Durbin et al. 1998). Ephrins control migration of neural crest cells into 
branchial arches and somites (Krull et al. 1997; Smith et al. 1997; Wang and 
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Anderson 1997). In these systems, ephrin–Eph interactions are thought to be mainly 
repulsive, that is, navigating growth cones or migrating cells expressing Eph 
receptors would turn away from cells expressing the corresponding ephrin ligand 
(Drescher et al. 1995; Nakamoto et al. 1996; Brennan et al. 1997; Krull et al. 1997; 
Wang and Anderson 1997). Repulsive interactions and complementary expression 
patterns suggest that ephrins and Eph receptors define spatial boundaries in the 
developing embryo (Gale et al. 1996). 
It is known that Eph receptor tyrosine kinases and their cell-surface-bound ligands, 
the ephrins, regulate axon guidance and bundling in the developing brain, control cell 
migration and adhesion, and help patterning the embryo (Adams et al., 1999). This 
working group also reported that two ephrin-B ligands (ephrin-B1 and ephrin-B2) and 
three EphB receptors (EphB2, EphB3 and EphB4) are expressed in and regulate the 
formation of the vascular network. Mice lacking ephrin-B2 and double mutants 
deficient in EphB2 and EphB3 receptor signalling die in utero because of defects in 
the remodelling of the embryonic vascular system. Interaction between ephrin-B2 on 
arteries and its EphB receptors on veins suggests a role in defining boundaries 
between arterial and venous domains. Expression of ephrin-B1 by arterial and 
venous endothelial cells and EphB3 by veins and some arteries indicates that 
endothelial cell-to-cell interactions between ephrins and Eph receptors are not 
restricted to the border between arteries and veins. Furthermore, expression of 
ephrin-B2 and EphB2 in mesenchyme adjacent to vessels and vascular defects in 
ephB2/ephB3 double mutants indicate a requirement for ephrin–Eph signalling 
between endothelial cells and surrounding mesenchymal cells. Finally, ephrin-B 
ligands induce capillary sprouting in vitro with a similar efficiency as angiopoietin-1 
(Ang1) and vascular endothelial growth factor (VEGF), demonstrating a stimulatory 
role of ephrins in the remodelling of the developing vascular system (Adams et al., 
1999). 
The assembly of endothelial cells and supporting mesenchyme into mature and 
functional blood vessels is a multi-step process involving a diverse array of molecular 
signals. Ligands for receptor tyrosine kinases (RTK) such VEGFs and angiopoietins 
are well known as critical mediators of blood vessel formation during embryogenesis. 
Expression of ephrin ligands and Eph receptors during embryogenesis is highly 
dynamic, with expressions in various sites during different stages of development 
(Holder and Klein, 1999). These sites include the organizer, or node, during 
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gastrulation, different rhombomere segments during hindbrain patterning, neural 
crest cells that migrate to branchial arches during cranial morphogenesis, somites, 
and developing vasculature. Recently, class B members of the Eph/ephrin family 
have also been described in the developing cardiovascular system. Most 
interestingly, expression of LacZ reporter gene under the control of endogenous 
ephrin-B2 or EphB4 promoter/enhancer in mice lacking one allele of ephrin-B2 or 
EphB4 revealed complementary expression of ephrin-B2 in arterial endothelial cells 
and its cognate receptor, EphB4 in venous endothelial cells (Wang et al., 1998). 
Although later studies also found low levels of EphB4 on arterial endothelial cells and 
ephrin-B2 on paravascular supporting cells (Adams et al., 1999), ephrin-B2 and 
EphB4 are the best markers available for arterial and venous endothelial cells at very 
early stage of development. Other EphB molecules were also expressed at the sites 
of neovascularization. Ephrin-B1 is co-expressed with EphB1 in endothelium in the 
developing kidney (Daniel et al., 1996). EphB3 is expressed predominantly in veins, 
as is EphB4, but is also detected in some arteries such as those found in the yolk sac 
(Adams et al., 1999). In addition to expression in endothelial cells, ephrin-B2 and 
EphB2 are also expressed in mesenchymal supporting cells, suggesting a role of Eph 
receptors and ephrin ligands in vessel wall development through interactions 
between endothelium and mesenchyme (Adams et al., 1999). 
 
1.6. EFNB1 gene and CFNS 
 
Human EFNB1 (OMIM 300035) gene is located on the X-chromosome (Xq12-
Xq13.1) in contrast to EFNB2 and EFNB3 genes that are located on the 13th 
(13q33.3) and 17th (17p13.1) chromosomes respectively. The genomic length of 
EFNB1 is 13,17 Kb including the 8,7 Kb first intron, coding part consists of 1041 bp 
and encodes a polypeptide of 346 amino acids. EFNB1 consists of 5 exons and 4 
introns. Exons 2 and 3 (278 bp and 93 bp, respectively) encode the extracellular 
ephrin domain, exon 5 is 413 bp long and encodes transmembrane and intracellular 
domains. Exon 1 is 128 bp long and encodes the signalling peptide and exon 4 is 
129 bp long and encodes a protein link between extracellular domain and the 
transmembrane part. 
Most EFNB1 mutations responsible for CFNS constitute point mutations, small 
deletions, insertions or duplications (Shotelersuk et al., 2006; Torii et al, 2007; Twigg 
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et al., 2004; Twigg et al., 2006; Vasudevan et al., 2006; Wieland et al., 2004; Wieland 
et al., 2005). Mutations of EFNB1 were detected in CFNS patients in both familial and 
sporadic cases. Partial or complete EFNB1 gene deletions were described in only 
several CFNS cases (Twigg et al., 2006; Wieland et al., 2004; Wieland et al., 2007). 
The major types of mutations (up to 55%) are frameshift, nonsense, and splice site 
mutations that lead to premature termination codons (PTCs). Missense mutations 
constitute about 42% of all EFNB1 mutations (Twigg et al. 2004; Wieland et al. 2005). 
Most of them occur in exons 1-4 (ephrin extracellular domain), leading to the 
exchange of amino acid residues that are important for receptor–ligand interaction 
and bi-directional signalling. Nonsense mutations were found mostly in exons 1-3 
(Wieacker and Wieland, 2005; Twigg et al., 2006). Frameshifts were detected in all 5 
exons of EFNB1. Loss of gene function has been proposed for most mutations and 
has been shown for some of them, but it has not been proven for missense 
mutations, splice site mutations, and for mutations causing premature termination in 
exons 4 and 5 (Shotelersuk et al. 2006; Twigg et al. 2006; Wallis et al. 2008; Wieland 
et al. 2004, 2007, 2008). 
Twigg et al. (2006) showed that ≈92 % of all de novo germline EFNB1 mutations 
had a paternal origin. Also this working group reported that these mutations 
appeared in the male germline independently from the paternal age. The major part 
of EFNB1 mutations occurs de novo. Wieland et al. (2005) described 26 novel 
mutations, sporadic cases consist 78,8 % of them, Twigg et al. (2006) described 39 
new EFNB1 mutations, sporadic cases consist 61,5 % of them. Some mutations such 
as c.196C>T/R66X and c.161C>T/p.P54L were detected both in family and sporadic 
patients (Twigg et al., 2006, Wieland et al., 2004; Wieland 2005). It was calculated 
that 80% of individuals harbouring EFNB1 mutations would be female, which accords 
with clinical observations (Twigg et al., 2006). 
Alternative splicing of the EFNB1 gene is caused by splice-site mutations including 
the c.406+2T>C mutation that is described in this work. No alternative splice-site 
variants were described in normal situation till now. 
More than 100 SNPs have been described for EFNB1 gene (NCBI SNP database 
http://www.ncbi.nlm.nih.gov/SNP/). 
It was proposed by John et al. (2004) that expression of EFNB1 is controlled by 
miRNA. This working group has identified miRNAs that can target ephrin-encoding 
genes (five genes including EFNB1 out of seven genes). Although, many members of 
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the ephrin family are predicted targets of brain-expressed miRNAs, they appear to be 
targeted by different miRNAs, consistent with differential regulation (John et al., 
2004). 
MicroRNAs (miRNAs) interact with target mRNAs at specific sites to induce 
cleavage of the message or inhibit translation. Several hundred genes encoding 
transcripts containing short double-stranded RNA hairpins, named microRNAs 
(miRNAs), are identified in plants and animals up to now (Lee et al. 1993; Reinhart et 
al., 2002; Lagos-Quintana et al. 2001, 2002, 2003; Lau et al. 2001; Lee and Ambros 
2001; Mourelatos et al. 2002; Ambros et al. 2003; Aravin et al. 2003; Brennecke et al. 
2003; Dostie et al. 2003; Grad et al. 2003; Houbaviy et al. 2003; Lai et al. 2003; Lim 
et al. 2003a, 2003b). The cellular functions of most animal miRNAs are unknown. In 
eukaryotes miRNA genes constitute about 1%–2% of the known genes. 
MicroRNAs working mechanism has specificity. In living organisms, miRNAs are 
differentially expressed in developmental stages, cell types, and tissues (Lee and 
Ambros 2001; Lagos-Quintana et al. 2002; Sempere et al. 2004). In particular, 
differential expression has been observed in mammalian organs (Lagos- Quintana et 
al. 2002; Krichevsky et al. 2003; Sempere et al. 2004) and embryonic stem cells 
(Houbaviy et al. 2003). 
MicroRNAs cause the translational repression or cleavage of target messages 
(Doench and Sharp 2004). Some miRNAs work like small interfering RNAs (siRNAs). 
They direct mRNA cleavage between the nucleotide positions 10 and 11 in the 
siRNA:mRNA target duplex (Tuschl et al. 1999; Zamore et al. 2000; Elbashir et al. 
2001; Hutvágner and Zamore 2002a; Martinez et al. 2002; Bartel 2004; Yekta et al. 
2004). Extent of base pairing between the small RNA and the mRNA determines the 
balance between cleavage and degradation (Hutvágner and Zamore 2002b). 
Cleavage of mRNA is a straightforward process, but the details of the mechanism of 
translational repression are still unknown. The rules of regulation in the siRNA 
pathway also apply to miRNA target recognition (Hutvágner and Zamore 2002b; 
Doench et al. 2003). 
It was reported recently that Notch signalling activates the expression of EFNB1 
gene in mouse intestinal epithelium (Koo et al., 2009). 
More than 100 SNPs have been described for EFNB1 gene (NCBI SNP database, 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp&cmd). But none was detected in 
any patient group. 
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Craniosynostosis is a common birth defect (1 in 2100–2500 infants) that affects 
the premature fusion of one or more of the cranial sutures and leads to an abnormal 
head shape (Feldman et al., 1997). Craniofrontonasal syndrome (CFNS; OMIM 
304110) is an X-linked craniofacial disorder and belongs to the heterogeneous group 
of craniofrontonasal dysplasia (CFND). It is characterized by craniofacial asymmetry, 
hypertelorism, coronal synostosis, strabismus, bifid nasal tip, grooved nails, 
abnormalities of the thoracic skeleton as well as wiry and curly hair. Polydactyly and 
syndactyly may also occur. Rare manifestations are anterior cranium bifidum, axillary 
pterygium, joint abnormalities, cleft lip and palate, unilateral breast hypoplasia, 
asymmetric lower-limb shortness, corpus callosum hypoplasia and aplasia, umbilical 
hernia, and diaphragmatic hernia (reviewed by Wieacker and Wieland, 2005). 
CFNS has a very unusual manifestation pattern, in which affected females show 
multiple skeletal malformations whereas only mild abnormalities such as 
hypertelorism are observed in male carriers (Feldman et al., 1997; Morris et al., 
1987). 
CFNS locus was located at Xp22 by Feldman et al. (1997). Linkage analysis 
performed by Wieland et al. (2002) revealed that a CFNS locus is located in the 
pericentromeric region of the X chromosome. The EFNB1 gene was mapped in 
Xq12-Xq13.1 that is included in the CFNS interval (Wieland et al., 2002, 2004). 
Compagni et al. (2003) reported that targeted inactivation of Efnb1 (the mouse 
homologue of EFNB1) in mice caused high perinatal lethality, abdominal wall closure 
defects, and skeletal abnormalities, especially of the thoracic cage. The phenotype is 
more severe in female heterozygotes than in hemizygous males, and some defects, 
such as preaxial polydactyly, were detected only in heterozygotes. The abnormalities 
of development in these mice looked like the symptoms of CFNS in human. 
Interestingly, it was shown, that homozygous female mice with both mutant alleles of 
Efnb1 have less severe manifestation than heterozygous females (Davy et al., 2006). 
Together the localization of the CFNS-locus (Wieland et al., 2002) and the result of 
Efnb1 knockout mice (Compagni et al., 2003; Davy et al., 2004) made EFNB1 a 
strong candidate gene for causing CFNS. Wieland et al. (2004) demonstrated that 
EFNB1 mutations cause CFNS. Mutations in EFNB1 were detected in the vast 
majority of patients with familial and sporadic craniofrontonasal syndrome (Wieland et 
al., 2005; Twigg et al., 2004). 
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1.7. Hypothesis of cellular interference 
 
As it was said before, CFNS is caused by EFNB1 mutations, and this gene is 
located on the X-chromosome. Surprisingly, female carriers with one mutant and one 
wild type EFNB1 alleles are affected more severely than male carriers, although male 
carriers do have neither wild type allele nor a homologue of the gene on the Y 
chromosome. How does it happen? 
Johnson (1980) proposed the hypothesis of metabolic interference to explain the 
situation. This hypothesis is suitable for the cases, when two allelic genes encode 
different subunits of a multisubunit enzyme or structural protein. 
Young and Moore (1984) proposed that CFNS caused male lethality. 
Ephrins are expressed in a complex and temporally dynamic pattern during 
embryogenesis. Wieland et al. (2004) assumed that, in heterozygous females, 
ephrin-B1–expressing and ephrin-B1–deficient cells lead to disturbance of cell sorting 
and migration. This group also proposed the “cellular interference” hypothesis. The 
core of this hypothesis is following. Somatic human cells have forty-six chromosomes 
as a diploid set including two sex chromosomes (XY in males and XX in females). 
   - EphB2-expressing cells   - ephrin-B1-positive cells 
   - ephrin-B1-mutant cells 
b Hemizygosity for CFNS 
mutation 
a Wild-type 
Fig. 2 Hypothesis of cell sorting in case of: a normal sorting; b male patient; c female 
patient. 
c Heterozygosity for CFNS 
mutation 
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Only one X-chromosome is active in a somatic cell – the single one in male cells and 
one of two in the female cells. In females the other X-chromosome is inactivated 
(Lyon, 1961) and subsists as a Barr body. This inactivation proceeds randomly in 
human. All females, including CFNS-patients, are functional mosaics because of this 
random X-inactivation. They have two different cell populations with different active 
X-chromosome. In case of female CFNS patients, cells of one population have the 
wild type EFNB1 on the active X-chromosome and cells of the other population have 
the mutant type on the active X-chromosome. CFNS is caused by different sorting of 
the cells depending on the expression of the wild type or the mutant type EFNB1 
alleles (Fig. 2c). This sorting proceeds depending on interaction of ephrin-B1 with 
EphB-receptors. In males, this interaction proceeds normally (wild type EFNB1, Fig. 
2a) or disturbed completely (mutant EFNB1) and, probably, rescued by some other 
ephrins (Fig. 2b). In females interaction proceed normally (wild type EFNB1, Fig. 2a) 
or disturbed partly due to random X-inactivation (mutant EFNB1) and, probably, 
partly rescued by some other ephrins (Fig. 2c). The interaction of EphB2-expressing 
cells with two populations of ephrin-B1-expressing cells (wild-type and mutant-type 
ephrin) is thought to be the major pathogenetic mechanism of this disease. The 
concept of cellular interference appears to be not unique for CFNS. Dibbens et al. 
(2008) described the molecular cause of epilepsy and mental retardation limited to 
females (EFMR, OMIM 300088). This X-linked disorder affects females, while male 
carriers are unaffected. EFMR is caused by mutations in PCDH19 gene encoding the 
cell-cell adhesion molecule protocadherin 19. Like in CFNS, somatic mosaicism may 
cause cellular interference leading to malformations in the brain and development of 
epilepsy (Lindhout 2008). This pathogenic mechanism has been strongly supported 
by a mosaic male patient harbouring a PCDH19 mutation, who was identified in a 
cohort of patients with Dravet syndrome-like epileptic encephalopathy (Depienne et 
al. 2009). 
 
1.8. The aims of the work 
 
The main aim of this work is expressional and functional analysis of different 
EFNB1 mutations. Several patient derived mutations have been analysed. The work 
can be divided into two parts. First premature termination codon (PTC)-causing 
mutations were analysed: frameshift mutation c.377_384delTCAAGAAG (PTC in 
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exons 2/3 junction), frameshift mutation c.614_615delCT (PTC in exon 4) and splice-
site mutation c.406+2T>C (PTC in intron 2 or exon 3). All three mutations were 
predicted in silico to result in a truncated, soluble ephrin-B1 protein. 
In the second part of this work the impact of missense mutations c.161C>T/p.P54L 
and c.332C>T/p.T111I on cell behaviour and reverse ephrin-B1 cell signalling was 
investigated. The role of these mutations was analysed in a cell culture model using 
NIH3T3 fibroblasts. To analyse the impact of missense mutations in ephrin-B1 
signalling the phosphorylation of t Tyr324 and Tyr329 amino acids in mutant and wild 
type ephrin-B1 was monitored after the EphB2-Fc stimulation. 
As it was told already, ephrin-B1 is expected to be involved in STAT3, TWIST1 
and MSX2 signalling pathways. According to that, the change of expression level of 
MSX2 and TWIST1 due to ephrin-B1 stimulation was monitored. 
 25
2. Materials and methods 
 
2.1. Cells cultures work 
 
2.1.1. Cell cultures maintaining 
 
Informed consent was obtained from the parents of the patients. Fibroblasts of 
CFNS patients were obtained from skin biopsies (c.377_384delTCAAGAAG and 
c.406+2T>C mutations) or surgical therapeutic interventions (c.614_615delCT) into 
the synostosis. Primary cell cultures of patient fibroblast cultures were maintained 
according to standard cell culture conditions in tissue culture flasks (Cellstar®) with 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma) containing 15 % fetal calf 
serum (FCS, Sigma) in a 5% CO2 atmosphere at 37oC. Every 4 days the exhausted 
medium was aspired and new medium added. Cells were harvested for genomic 
DNA and total RNA or protein isolation using Cell Scrapers (NUNC). 
NIH 3T3 cells were cultivated in tissue culture flasks (Cellstar®) with DMEM 
containing 15 % FCS, in a 5% CO2 atmosphere at 37oC. Every 4 days the exhausted 
medium was aspired and new medium added. Cells were harvested for genomic 
DNA and total RNA or protein isolation using Cell Scrapers. 
 
2.1.2. NIH 3T3 transfection 
 
NIH 3T3 cells were placed on a 6-well plate (Greiner Labortechnik) at a ratio 1×105 
cells/well, cells were counted using the cell counting camera (Neubauer). Cells were 
cultivated until they reached 70% confluence (usually within 24 h). Plated cells were 
cotransfected with pcDNA 3.1(+) vector (Invitrogen) containing the mutant or the wild 
type EFNB1 cDNA (4 µg/well) and the pEGFP-N3 vector (4 µg/well, BD Biosciences). 
Transfections were done using PerFectinTM Transfection reagent (PeqLab) according 
supplied protocol with modifications: 
1. The cells were plated one day before transfection, so that they would be 
70% confluent on the day of transfection. 
2. On the day of transfection the hydrated PerFectin reagent was diluted with 
serum-free medium at a ratio: 28 µl PerFectin + 172 µl of serum-free 
medium per transfection reaction. 
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3. DNA was diluted with the DNA diluent at a ratio: 8 µg DNA + 200 µl diluent 
per transfection reaction. The solution was mixed well by pipetting several 
times and incubated for 5 min at room temperature. 
4. After the 5 min incubation the DNA solution was added to the diluted 
PerFectin reagent. The mix was incubate at room temperature for 30 min to 
form PerFectin /DNA complexes (lipoplexes). After the incubation serum-
free medium was added to the complexes to make up the transfection 
volume up to 1 ml per reaction. 
5. The culture medium was aspirated from cells and cells were washed with 
PBS (Sigma). 
6. Solution from the p. 6 was added to the cells (1 ml per well). Cells were 
incubated for 4 hours at 37oC and 5% CO2. 
7. One volume of the medium containing 20% serum (1 ml per well) was 
added to the transfection reactions. 
8. Fresh growth media was added 24 hours post transfection (1 ml per well). 
9. The reporter gene assay was performed 24 to 72 hours following the 
transfection. 
Transfection efficiency was measured using fluorescent cytometry cell sorting 
(FACS) 24 h post transfection as described below. 
 
2.1.3. FACS analysis 
 
Transfected cells were washed in PBS and treated with trypsin (Sigma) 24 h post-
transfection. After the treatment, PBS was added and part of the cells was taken as a 
sample for the FACS analysis. FACS was performed using the ectopic GFP-
fluorescence in BD FACSCantoTM Flow Cytometer (BD Bioscience), 3×104 events 
were counted. Untransfected NIH 3T3 cells were used as a control. 
 
2.1.4. NIH 3T3 stimulation 
Stimulation of NIH3T3 cells with EphB2-receptor was performed according to a 
modified protocol of Davy et al. (2006): 
1. The medium was aspired 32 h posttransfection, the cells were washed 
twice with PBS, the remaining liquid was drained off and cells starved 16 h 
in medium, containing 0,5 % serum. 
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2. EphB2-Fc/Fc (R&D Systems) was preclustered with anti-human rabbit IgG 
(R&D Systems) at a ratio 1:2 for 30 min at room temperature (EphB2-Fc/Fc 
was diluted to concentration 50 µg/ml with the serum-free medium). 
Preclustered EphB2-Fc/Fc was diluted to 4 µg/ml with the serum-free 
medium before adding to the cells. Preclusterization was performed directly 
before the stimulation 
3. The low-serum medium was aspired, cells were washed twice with PBS, the 
remaining liquid was drained off and preclustered EphB2-Fc/Fc containing 
medium was added. 
4. Cells were incubated for 5 to 30 min at 37oC, washed in PBS and cultivated 
in DMEM with 15 % FCS as described above. 
As a control, stimulation with preclustered Fc (R&D Systems) was performed. 
 
2.1.5. Patches formation analysis 
 
NIH 3T3 cells were transfected as it is described above, pictures of the transfected 
cells were taken 32 h posttransfection, just before the stimulation. Transfected NIH 
3T3 were stimulated as it is described above. Stimulation lasts for 30 minutes. 
Patches formation analysis was done 24 h after the stimulation by taking photos. 
Pictures were taken by fluorescent microscopy method using Axiovert 25 Inverse 
Microscope and AxioCam MRc5 0450-354, Carl Zeiss. 
 
2.2. Molecular methods 
 
2.2.1. DNA extraction from fibroblasts 
 
Extraction of DNA from fibroblasts was performed as it is described in Maniatis 
(1989) with changes: 
1. The cells were washed twice with PBS (1ml/25cm2), every time cells were 
scraped with a Cell Scraper into a microcentrifuge tube (Eppendorf). 
2. The tubes with DNA were centrifuged for 5 min at 2500 min-1 at 4oC 
3. PBS was aspired and the pellet was resuspended in of OLD-T buffer 
(40mM Tris/HCl, 150mM NaCl, 25mM EDTA, pH 7,5; 500 μl OLD-T 
buffer/1ml PBS). 
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4. Proteinase K (Merck) was added to the mix to a final concentration 1 g/l and 
the mix was incubated for overnight at 55oC. 
5. After the incubation, 1 volume of phenol (ROTH) was added and the 
solution was mixed gently for 3-5 min. The two phases were separated by 
centrifugation for 5 min at 2500 min-1 at room temperature and the aqueous 
(upper) phase was transfer into the new microcentrifuge tube. 
6. 1 volume of phenol-chloroform mix (1:1) was added and the solution was 
mixed gently for 3-5 min. The two phases were separated by centrifugation 
for 5 min at 2500 min-1 at room temperature and the aqueous (upper) phase 
was transfer into the new microcentrifuge tube. 
7. 1 volume of chloroform (ROTH) was added and the solution was mixed 
gently for 3-5 min. The two phases were separated by centrifugation for 5 
min at 2500 min-1 at room temperature the aqueous (upper) phase was 
transfer into the new microcentrifuge tube. 
8. The DNA was precipitated with 2 volumes of 96% ethanol. 
9. DNA was transferred into the new 1,5 ml tube with a sterile glass stick, 
dried for 3-5 min. and dissolved in 50-100 µl of TE buffer (10 mM Tris-HCl 
(pH 8,0), 1 mM EDTA (pH 8,0), pH 8,0; Maniatis, 1989). 
 
2.2.2. Mutation detection 
 
Mutations were detected by direct sequencing with the MegaBace sequence 
analyser (GE Healthcare) and DYEnamic ET terminator cycle sequencing kit (GE 
Healthcare), as it is recommended by its protocol. 
The sequencing data were compared with EFNB1 reference sequence GenBank 
accession number NM_004429.4 and NG_008887.71 and Ensembl number 
ENST00000204961. Mutations were confirmed by exon-specific PCR amplification 
and restriction enzyme digestion in all of the primary cell cultures. PCR primers were 
5’-CAAGTTCCTGAGTGGGAAGG-3’ and 5’-GTGTGGCCATCTTGACAGTG-3’, 
producing a 455bp fragment containing exons 2-4 for analysis of 
c.377_384delTCAAGAAG mutation; 5’-GGCTCTTGTCCGCTTCCCTG-3’ and 5’-
CCAGTCTTCAAAGGGGATCA-3’ producing a 502 bp fragment containing exon 2 
and intron 2 for analysing c.406+2T>C mutations, primer pair 5’-
AGGAACAGTCAGCCAGGGG-3’ and 5’-GGGGAGCAGGCGTAGGGTTA-3’ 
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producing a 377 bp product containing exon 4 was used for analysing 
c.614_615delCT. Primers were designed using the program Primer3 v.0.4.0 
http://frodo.wi.mit.edu). Mutations c.377_384delTCAAGAAG and c.614_615delCT 
were detected by HinfI restriction enzyme (New England Biolabs) cleavage of the 
PCR-products, mutation c.406+2T>C was detected by BfuAI restriction enzyme (New 
England Biolabs) cleavage of the PCR-products. Primers were provided by PD Dr. I. 
Wieland. Analysis of the restriction fragments was performed using the agarose gel-
electrophoresis, 100 bp DNA Ladder by NEW ENGLAND BioLabs was used as a 
control. 
 
2.2.3. RNA extraction with NucleoSpin® RNA / Protein 
 
Extraction of RNA was performed using the NucleoSpin® RNA / Protein kit 
(MACHERY-NAGEL) according to the supplier protocol: 
1. 105 eukaryotic cultured were collected by centrifugation and lysed by 
directly addition of Buffer RP1. 
2. 350 µl Buffer RP1 and 3.5 µl ß-mercaptoethanol (J.T.Baker) were added 
to the cell pellet and the mix was vortexed vigorously. 
3. The mix was filtered through the NucleoSpin® Filter as it is recommended 
by the supplier: centrifugation for 1 min at 11,000 x g. 
4. NucleoSpin® Filter was discarded and 350 µl ethanol (70 %) was added to 
the flow-through. The mix was pipetted up and down approx. 5 times. 
5. For each RNA extraction, one NucleoSpin® RNA/Protein Column was 
used. It was placed in a collection tube and the lysate was transferred into 
the column. As it is recommended by the supplier, the column was 
centrifuge for 30 s at 11,000 x g. After the centrifugation the column was 
placed in a new collection tube (2 ml, supplied with the kit). 
6. 350 µl MDB (Membrane Desalting Buffer) were added into the Column 
and it was centrifuged at 11,000 x g for 1 min to dry the membrane. 
7. Meanwhile the rDNase reaction mixture was prepared in a sterile 
microcentrifuge tube. For each isolation, as it was recommended by the 
supplier the DNA restriction mixture was composed as follows: 10 µl 
reconstituted rDNase and 90 µl Reaction Buffer for rDNase were mixed by 
flicking the tube gently, 95 µl of the rDNase reaction mixture was applied 
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directly onto the centre of the silica membrane of the column and the 
column was incubated at room temperature for 15 min. 
8. The NucleoSpin® RNA/Protein Column was washed with 200 µl of Buffer 
RA2 (centrifugation for 30 s at 11,000 x g). After centrifugation the 
NucleoSpin® RNA/Protein Column was transferred into a new collection 
tube (2 ml). 
9. The NucleoSpin® RNA/Protein Column was washed with 600 µl of Buffer 
RA3 (centrifugation for 30 s at 11,000 x g). The flow-through was 
discarded, the column was placed back into the same collection tube. 
10. The NucleoSpin® RNA/Protein Column was washed with 250 µl of Buffer 
RA3 (centrifugation for 2 min at 11,000 x g to dry the membrane 
completely). After centrifugation the NucleoSpin® RNA/Protein Column 
was transferred into an RNase-free Collection Tube (1.5 ml, supplied with 
the kit). 
11. The RNA was eluted with 60 µl RNase-free H2O (supplied with the kit) by 
centrifugation at 11,000 x g for 1 min. 
 
 
2.2.4. RT-PCR and cloning 
 
For expression analysis and generating the p.P54L and p.T111I constructs by in 
vitro site-directed mutagenesis total RNA was reverse transcribed using Super 
ScriptTM One-StepTM RT-PCR System (Life Technologies) following the protocol: 
1. The PCR reaction was assembled was assembled as follows: 
 Oligo dT primer (0.5 g/l)   0.5 µl 
 pd(N)6 Random primer (0.2 g/l)     1 µl 
 10 mM dNTP Mix       1 µl 
 RNA         2 µg 
 MQ H2O        up to 12 µl 
2. The reaction mixture were mixed gently and incubated at 65oC for 5 min. 
3. After the 65oC incubation the mix was incubated on ice for 15 min. 
4. After the ice incubation following reagents were added into a PCR reaction 
tube: 
 5x PCR buffer (200mM Tris-HCl (pH 8.4), 500 mM KCl, Invitrogen) 4 µl 
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 0,1 M DTT (Invitrogen)  2 µl 
 RNAse OUT (Invitrogen)  1 µl 
 Superscript II (Invitrogen)  1 µl 
5. The reaction was mixed gently and incubated at 42oC for 1 h. 
6. After the 42oC incubation, PCR reaction was incubated at 70oC for 15 min. 
7. After the 70oC incubation, PCR reaction was put on ice for 15 min for 
immediate use or frozen. 
For analysis of PTC-causing mutations primer pair 5’-
CAAGTTCCTGAGTGGGAAGG-3’ and 5’-GTGTGGCCATCTTGACAGTG-3’ was 
used to amplify a 455 bp product from exons 2-4, primer pair 5’-
GGCTCTTGTCCGCTTCCCTG-3’ and 5’-CCAGTCTTCAAAGGGGATCA-3’ was 
used to amplify a 502 bp product from exon 2 and intron 2 and primer pair 5’-
ATCATGAAGGTTGGGCAAGA-3’ and 5’-TGGGGGCAGTAGTTGTTCTC-3’ was 
used to amplify a 467 bp product from exons 4 and 5 of EFNB1. All primers were 
provided by PD Dr. I. Wieland. 
455 bp fragment was constructed using the following program: 
1. 94oC    3 min 
2. 94 oC    1 min 40 cycles 
 59 oC  45 sec 
 72 oC  45 sec 
3. 72 oC  45 sec 
467 bp fragment was constructed using the following program: 
1. 94oC    3 min 
2. 94 oC    1 min 50 cycles 
 55 oC  45 sec 
 72 oC  45 sec 
3. 72 oC  45 sec 
502 bp fragment was constructed using the following program: 
1. 94oC    3 min 
2. 94 oC    1 min 50 cycles: 
 63 oC  45 sec 
 72 oC  45 sec 
3. 72 oC    1 min 
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For generating the p.P54L and p.T111I constructs, amplification of EFNB1 cDNA 
was performed using 5’-GGCAGAGGAAGGCGAGGCGA-3’ and 5’-
GCAAGGGGAGGGGGTGTG-3’ primer pair that generates a 1,2 Kb product. 
1,2 Kb fragment was constructed using the following program: 
1. 94oC    2 min 
2. 94 oC  10 sec 10 cycles 
63 oC  30 sec 
68 oC    2 min 
3. 94 oC  15 sec 10 cycles: 
63 oC  30 sec 
68 oC    5 min 
4. 72 oC  45 sec 
 
2.2.5. Real-time RT-PCR 
 
Quantitative RT-PCR analysis was performed using an iQTM SYBR green 
supermix kit (Bio-Rad Laboratories GmbH) according to the kit’s protocol. Primer pair 
5’-CAAGTTCCTGAGTGGGAAGG-3’ and 5’-GTGTGGCCATCTTGACAGTG-3’ was 
used to amplify a 455 bp product from exons 2-4 of EFNB1, the program is described 
in section “RT-PCR”. Primer pair 5’-TCACAGAGACCCAGGTCAAA-3’ and 5’-
GGATGGGAAGCACAGGTCTA-3’ was used for MSX2. 
For every real-time PCR reaction the mix was prepared as follows: 
1. SYBR green supermix   12,5 µl 
2. Primer 1 (2 pmol/μl)        1 μl 
3. Primer 2 (2 pmol/μl)        1 μl 
4. DNA           1 µg 
5. MQ water         up to 25 μl 
The following program was used for MSX2 amplification: 
1. 95oC    4 min 
2. 95 oC    1 min 50 cycles 
60 oC  45 sec 
72 oC  45 sec 
3. 72 oC  45 sec 
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Primer pair 5’-CTCGGACAAGCTGAGCAAG-3’ and 5’-
TTTTTAGTTATCCAGCTCCAGAGTC-3’ was used for TWIST1. 
The following program was used for TWIST1 amplification: 
1. 95oC    4 min 
2. 95 oC  45 sec 50 cycles 
58 oC  45 sec 
72 oC  45 sec 
3. 72 oC  45 sec 
 
Real-time amplification was performed by iCyler iQTM Real Time PCR Detection 
System (Bio-Rad). The threshold cycle number (Ct) was measured using the iCycler 
and its associated software. To calculate the relative expression of gene of interest, 
the cDNA from housekeeping gene G3PDH was used as a control, primer pair 5'-
TGGTATCGTGGAAGGACTCA-3' and 5'-ATGCCAGTGAGCTTCCCGTT-3' (Wieland 
et al., 1999) was used for the amplification. 
The following program was used for G3PDH amplification: 
1. 94oC    3 min 
2. 94 oC    1 min 50 cycles 
62 oC  45 sec 
72 oC  45 sec 
3. 72 oC  45 sec 
Gene of interest mRNA expression was normalised with G3PDH mRNA 
expression by calculating Δ(ΔCt) as it is described by Livak and Schmittgen (2001). 
Relative levels were calculated by the 2-Δ(ΔCt) method. Results are given as fold 
differences to control primary fetal fibroblasts (Livak and Schmittgen, 2001). For each 
PCR the melting curves were generated to ensure the purity of the amplification 
product. 
 
2.2.6. Generation of the mutant EFNB1 cDNA constructs by site-directed in 
vitro mutagenesis 
 
EFNB1 RNA preparation from placenta, reverse transcription and EFNB1 cDNA 
amplification were performed as described above. This 1,2 Kb RT-PCR product was 
cloned into the pCR 2.1 vector (Invitrogen). Mutant EFNB1 cDNA containing 
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c.161C>T and c.332C>T mutations were generated using EFNB1-specific primers: 
5’-GGGCTTGGTGATCTATCTGAAAATTGGAGACAAGC-3’ and 5’-
GCTTGTCTCCAATTTTCAGATAGATCACCAAGCCC-3’ for c.161C>T, 5’-
CAGAGCAGGAAATACGCTTTATAATCAAGTTCCAGGAGTTCA-3’ and 5’-
CTGAACTCCTGGAACTTGATTATAAAGCGTATTTCCTGCTCTG-3’ for 
c.332_333CC>TA (nucleotide exchanges are underlined; primers were designed 
using the web-based primer software program http://labtools.stratagene.com/QC). 
Site-directed in vitro mutagenesis was performed using QuikChange® II Site-
Directed Mutagenesis Kit (Stratagene) according to its protocol: 
The following program was used: 
1. 95oC  30 sec 
2. 95 oC  30 sec 40 cycles 
55 oC    1 min 
68 oC    5 min 
3. 68 oC    1 min 
After the PCR reaction a Dpn I treatment was performed: 
1. PCR mix was incubated at 4oC for 15 min. 
2. 1µl of Dpn I (10U/µl) was added to each reaction and the mix was 
incubated at 37 oC for 1 h. 
In patient nucleotide exchange c.332C>T leads to the codon exchange ACC>ATC 
and amino acid exchange threonine to isoleucine. In this work nucleotide exchange 
c.332_333CC>TA was used. It leads to the codon exchange ACC>ATA and the 
same amino acid exchange. That was done because the threonine codon ATA is 
more frequently used then ATC. 
After the sequencing, wild type and mutant EFNB1 cDNA inserts were recloned in 
pcDNA 3.1(+) vector (BD Biosciences) using EcoRI restriction enzyme (MBI 
Fermentas). 
 
2.2.7. Sequencing 
 
The presence of mutations was confirmed by sequencing using ALFExpress 
sequencing machine (Amersham Biosciences) and the Cy5TM AutoReadTM 
Sequencing Kit (Amersham Biosciences) according to the modified kit’s protocol: 
I. The standard annealing of primer to double-stranded template was performed. 
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1. Mix with the following reagents was assembled in the 1,5 microcentrifuge 
tube: 
Template DNA   32 µl 
2 M NaOH     8 µl 
Total volume   40 µl 
2. The mix was vortexed gently, than briefly centrifuged and then incubate at 
room temperature for 10 min. 
3. After the incubation 7 µl of 3 M sodium acetate (pH 4.8), 4 µl of dH2O and 
120 µl of 100% ethanol were added into the tube. The reaction was mixed 
and frozen for 15 min. 
4. After that the DNA was precipitated by centrifugation for 30 min at 10 000 
min-1 at 4oC. 
5. The supernatant was discarded and the pellet was rinsed with 70% 
ethanol. The pellet was recentrifuged again for 15 min, 10 000 min-1, 4oC, 
and the supernatant was discarded. The pellet was dried for 5 min under 
the medium vacuum. 
6. Dry pellet was resuspended in 10 µl of distilled water. 
7. Then the following reagents were added to the resuspended pellet: 
 Cy5 Primer (4-10 pmol)       2 µl 
Annealing buffer        2 µl 
 Total volume (including the resuspended pallet)  14 µl 
8. The mix was gently vortexed and briefly centrifuged. The annealing 
reaction was incubated at 65oC for 5 min. Immediately after the 65oC 
incubation, the reaction was placed at 37oC and incubated for 10 min. 
After that the tube was placed at room temperature for some time (longer 
than 10 min). 
During the room temperature incubation wells of the MicroSample Plate 
(NUNC) was labelled “A”, “C”, “G” and “T” respectively, 2,5 µl of the “A” 
Mix, “C” Mix, “G” Mix and “T” Mix were pipetted into the corresponding 
labelled wells, respectively, (all procedures were done at 4oC). 
9. Annealing reaction was centrifuged briefly and 1 µl of Extension Buffer and 
3 µl of DMSO were added into the tube. Immediately after that the 
sequencing reaction was started. 
II. Sequencing Reaction. 
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1. MicroSample Plate with “A”, “C”, “G” and “T” Mixes were placed in a water 
bathe (37oC) for at least 1 min. All the following steps were performed at 
37oC. 
2. 2 µl of diluted T7 DNA Polymerase were added to the annealing reaction 
and the reagents were mixed thoroughly with a pipette tip. Immediately 
after that 4.5 µl of this mixture were transferred into each of the 
prewarmed sequencing mixes and incubated for 5 min. 
3. 5 µl of Stop Solution were added to each reaction and the reaction was 
mixed by gentle agitation. After adding the Stop Solution the reaction was 
heated to 88oC for 3 min and then immediately quenched on ice; 5 µl of 
“A”, “C”, “G” and “T” sequencing reactions were loaded into the 
appropriate wells of a sequencing gel. 
 
2.2.8. Western blot analysis 
 
Patient fibroblasts were lysed with RIPA buffer (30 mM Tris-HCl (pH 7,5), 0,12 M 
NaCl, 10% Glycerol and 1% Triton X100 as described by Harlow and Lane, 1988) 
and used for the SDS-PAGE Western blot analysis. Gel-electrophoresis was 
performed using MINI PROTEAN IITM electrophoresis devise (BIO-RAD) and 10% 
polyacrylamide TRIS-HCl gels (BIO-RAD). Blotting was performed in TRANS-BLOT® 
SD SEMI-DRY TRANSFER CELL (BIO-RAD) using the PVDF Transfer Membrane 
(HEHTM Life Science Product Inc.). Anti-ephrin-B1 antibody (A-20, Santa Cruz 
Biotechnology, Inc.) was used at a ratio 1:200 as it is recommended by the supplier, 
incubation was overnight at 4oC. As a control a Precision Plus Protein Standard Dual 
Color (BIO-RAD) was used. 
NIH 3T3 cells were washed with PBS and lysed in RIPA buffer containing 
PhosphoStop solution (1 tablet per 10 ml of RIPA buffer, Roche) immediately after 
the EphB2-Fc stimulation. Lysates were kept on ice and used for the SDS-PAGE 
Western blot analysis. Phospho-Ephrin B (Tyr324/329) antibody (Cell Signaling 
Technology®) was used at a ratio 1:1000 as it is recommended by the supplier, 
incubation was overnight at 4oC, and anti-ephrin-B1 antibody (A-20) was used to 
detect ephrin-B1. VisualizerTM Western Blot Detection Kit (UPSTATE) was used 
according to the protocol for visualization of the bands: 
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1. Detection reagents A and B were mixed at a ratio 1:2 respectively (final 
volume was approximately 3 ml for a single mini-gel sized blot, 3 ml per 50 
cm2 of membrane) and incubated for 1 h at room temperature. 
2. After the incubation, mix was pipetted onto the blotted membrane and 
incubated for 5 minutes at room temperature 
3. The membrane was removed from the mix, rinsed with MQ water and 
placed into the Saran wrap. 
4. The membrane was exposured with the X-ray film, exposure time is 5”-3’. 
 
All experiments were performed at least twice to reproduce the results. 
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3. Results 
 
3.1. Molecular analysis of the PTC-causing EFNB1 mutations in 
patient fibroblasts 
 
3.1.1. Frameshift mutation c.377_384delTCAAGAAG 
 
In this work three PTC-causing mutations were analysed. All three were predicted 
to be protein-truncating mutations. But usually PTC lead to the NMD, that is why first 
the mRNA level of these mutations was investigated. 
Frameshift mutation c.377_384delTCAAGAAG generates a premature termination 
codon (PTC) 17 nucleotides upstream of exon 2/exon 3 junction. RT-PCR analysis 
showed that primary patient fibroblast culture has very low level of the mutant EFNB1 
expression. One possible explanation was preferentially inactivation of the mutant 
EFNB1 carrying X-chromosome, another explanation was degradation of the mutant 
EFNB1 transcript. HUMARA showed random X-inactivation in the primary culture (not 
∅
Fig. 3. Analysis of c.377_384delTCAAGAAG fibroblasts. a. RT-PCR analysis of EFNB1
transcripts expressed in subclones of primary patient fibroblasts. RT-PCR products were
digested by Hinf I. Cell clone Ks1 showed expression of the wild type allele, (455 bp fragment,
indicated by arrow), whereas Ks20 showed only a very low level of mutant allele (digested into
the 199 bp and 248 bp fragments, indicated by arrowheads). Band with the size ≈455 bp that
was detected in Ks20 appeared to be the unspecific one. b. HUMARA analysis of Ks1 and
Ks20 clones. A clonality of Ks1 and Ks 20 was demonstrated. Ks1 has one X-chromosome
inactiveted whereas Ks20 has another X-chromosome inactived. 
RT-PCR 
455
248 
199 
M - Ks1 Ks20 
Hinf I 
HUMARA 
Ks1   Ks20 
Hpa II
a. b.
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shown) that excluded the preferentially inactivation of the mutant EFNB1 carrying X-
chromosome. To analyse the possibility of mRNA degradation, fibroblasts were 
subcloned into several subclones. Clonality of two of them, Ks1 and Ks20 was 
proven by HUMARA (Fig. 3b). It showed that in Ks1 one X-chromosome is 
inactivated whereas in Ks20 another X-chromosome is inactivated (Fig. 3b). The 
results of HUMARA are provided by PD Dr. I. Wieland. RT-PCR with following Hinf I 
digestion showed that one of these clones – Ks20 expresses only the mutant allele 
(447 bp RT-PCR product, digested by Hinf I into 199 bp and 248 bp fragments) while 
Ks1 clone express only the wild type EFNB1 allele (455 bp RT-PCR product). Also 
Ks20 appeared to have a very much lower level of EFNB1 expression (Fig. 3a). To 
measure the decrease of EFNB1 expression level, a real-time PCR was performed 
(Fig. 4). Fibroblasts were harvested for the RNA extraction using the NucleoSpin® 
RNA / Protein kit (MACHERY-NAGEL). To exclude the mistakes caused by the 
natural variations of the genes expression a housekeeping gene G3PDH was used 
as a control. Real-time PCR showed that primary patient fibroblasts have ≈8,42%, 
Ks1 clone has ≈8,85% and Ks20 has only ≈0,55% of EFNB1 expression compared to 
normal fibroblasts. It was proposed that decrease of EFNB1 expression level is 
caused by nonsense-mediated mRNA decay (NMD, Wieland et al., 2008). 
 
0
2
4
6
8
10
12
14
p Ks1 (wt) Ks20 (mut)R
el
at
iv
e 
EF
N
B
1
 m
R
N
A
 e
xp
re
ss
io
n 
  (
fo
ld
 
di
ffe
re
nc
e 
x 
10
-2
)
 
Fig. 4 Real-time PCR analysis of
c.377_384delTCAAGAAG 
subclones Ks1 and Ks20.
Fibroblasts were used for the RNA
extraction, RNA was reverse
transcribed to cDNA and used for
the real-time PCR. Primary patient
fibroblasts were shown to have
strong decrease of the EFNB1
expression compared to normal
fibroblasts. 
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3.1.2. Frameshift mutation c.614_615delCT 
Fig. 5 Expression of EFNB1 transcript and protein in primary patient fibroblasts harbouring
heterozygous frameshift mutation c.614_615delCT. a Sequence analysis of the patient
fibroblats. Uprer panel shows the wild type allele, lower panel shows the mutant allele. Deletion
of the CT dinucleotide creates a premature termination codon TGA in exon 4 (indicated by
arrows). b RT-PCR analysis of Er4 and Er6 clones. Er4 clone appeared to be expressing both
wild type and mutant EFNB1 alleles whereas clone Er6 express only wild type EFNB1 allele.
Wild type and mutant RT-PCR products were digested by the restriction enzyme Hinf I. Wild
type is digested to the 130 bp and 337 pb fragments (indicated by arrows), mutant allele is
undigested and indicated by an arrowhead (465 bp). Size markers are shown in lane M (100 bp
DNA ladder, Invitrogen). c Western blot analysis of ephrin-B1 expression in patient fibroblasts
culture. Wild type ephrin-B1 (≈50 kDa) was detected in both Er4 and Er6 (indicated by an
arrow). No smaller truncated protein corresponding to c.614_615delCT was detected at the
predicted molecular weight of ≈20 kDa in Er4 (expected size indicated by an arrowhead) using
an anti-ephrin-B1 antibody. 
c 
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Frameshift mutation c.377_384delTcAAGAAG was shown to cause transcript 
depletion by NMD (Wieland et al., 2008). However, escape from NMD was shown for 
c.614_615delCT mutation. This mutation is located in exon 4 of EFNB1 and cause 
PTC in 14 nucleotides upstream of 3’-end of the exon 4 (Wieland et al. 2008). 
In patient fibroblast cultures, RT-PCR revealed a mutant EFNB1 transcript in 
addition to the wild type transcript (Fig. 5a). In contrast to the 
c.377_384delTcAAGAAG mutation, the level of the c.614_615delCT mutant allele 
expression is not highly reduced. For the further investigation patient fibroblasts were 
recloned into several subclones. The results of the HUMARA were not informative 
(not shown). To distinguish wild type and mutant transcripts, RT-PCR analysis of the 
subclones was performed, the RT-PCR products were digested by Hinf I restriction 
enzyme. It was found out, that some of the analysed c.614_615delCT subclones 
(e.g. Er6) express only the wild type EFNB1 allele (467 bp RT-PCR product, digested 
into two fragments: 130 nucleotides and 337 nucleotides), whereas other subclones 
(e.g. Er4) are mixed i.e. they expresses both wild type and mutant (465 bp RT-PCR 
product) alleles (Fig. 5b). 
As it was told before, PTC containing mRNA was predicted to give rise to the 
truncated, soluble ephrin-B1 protein. To detect truncated ephrin-B1, proteins from 
Er4 and Er6 subclones were extracted and Western blot analysis was performed 
(Fig. 5c). In both subclones wild type ephrin-B1 (≈50 kDa) was detected as it was 
expected according to the results of the RT-PCR analysis. But the expected 
truncated protein (≈20 kDa) was not found in Er6 subclone that express both wild 
type and mutant EFNB1 alleles. 
 
3.1.3. Splice-site mutation c.406+2T>C 
 
In another girl from unaffected parents, de novo occurrence of the heterozygous 
splice-site mutation c.406+2T>C was detected in the genomic DNA (Fig. 6a, right 
panel). Splice-site mutation c.406+2T>C alters the consensus splice donor site “GT” 
of exon 2 at the junction of exons 2 and 3. 
Analysis of the patient fibroblasts by RT-PCR revealed that the wild type EFNB1 
transcript was the main transcript, but additional transcripts were derived from the 
splice-site mutation allele c.406+2T>C (Fig. 6b). This mutation leads to retention of 
intron 2 (corresponds to the 288 bp fragment, the Fig. 6b right panel) or to the 
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activation of a cryptic splice site within exon 2 (corresponds to the ≈1,2 Kb fragment, 
Fig. 6b right panel). Presence of the both splice variants has been confirmed by 
Ex 2  Ex 3 
cryptic splice site 
activation in exon 2 
genomic sequence 
Ex 2  In 2 
wild type cDNA 
Ex 2  Ex 3 
Ex 2  In 2 
retention of intron 2 RT-PCR 
p       pc1      pc2  
288 bp 
455 bp 
1200 bp 
control     patient
[kDa] wildtype 
ephrin-B1 50 
37 
25 predicted truncated 
ephrin-B1 
c 
a 
b 
Fig. 6 Expression of EFNB1 transcript and protein in primary patient fibroblasts harbouring splice
site mutation c.406+2T>C. a Sequence analysis of the patient genomic DNA. Nucleotide exchange
T>C in intron 2 at the splice donor site is indicated by an arrow (left panel). The major transcript 
expressed in patient fibroblasts was the wild type allele (right pannel). b RT-PCR analysis of the 
transcripts. Wild type and mutant transcripts in patient fibroblasts (lane p) and control cell cultures 
(lanes pc1 and pc2) were determined by RT-PCR. The wild type RT-PCR product is indicated by an 
arrow, mutant RT-PCR products are indicated by arrowheads. Sequencing of the aberrant
transcripts showed retention of intron 2 or activation of a cryptic splice site in exon 2 (left pannels). c
Western blot analysis of ephrin-B1 expression in patient fibroblasts and control cell culture lysates
showed an approximately 50 kDa protein (indicated by an arrow). No smaller truncated protein was
detected at the expected molecular weight of ≈10 kDa in patient fibroblasts. Protein sizes were 
determined using Precision Plus ProteinTM Standards Dual Color (BIO-RAD).  
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cDNA cloning and sequencing analysis (Fig. 6b left panel). 
Both splicing variants resulted in PTCs and were predicted to cause a truncated 
ephrin-B1 protein. To detect the truncated proteins, Western blot analysis was 
performed (Fig. 6c). As in case of c.614_615delCT mutation, the wild type ephrin-B1 
(≈50 kDa) but no truncated protein (≈10 kDa) was detected. Also Western blot 
revealed the band with ≈38 kDa size in both patient and control (transfected NIH 3T3) 
cells. This band has been detected several times. It was proposed that this band 
corresponds to the ephrin-B1 protein digested with γ-secretase (see above) or to the 
unglycosylated ephrin-B1. 
 
3.2. Analysis of missense mutations in a cell culture model 
 
3.2.1. Generation of c.161C>T/p.P54L and c.332_333CC>TA/p.T111I expression 
constructs and establishing the NIH 3T3 cell culture model 
 
The second most frequent type of mutation found in CFNS patients is missense 
mutations in exons 2 and 3 of EFNB1. Missense mutation c.161C>T in exon 2 has 
been recurrently detected in familial and sporadic CFNS patients. This mutation 
results in proline to leucine amino acid exchange in position 54 (p.P54L) of the 
extracellular ephrin domain (Wieland et al. 2004). Missense mutation c.332C>T is 
also located in exon 2 and has been previously described in a large German CFNS 
family (Wieland et al. 2004). This mutation changes threonine for isoleucine at 
ephrin-B1 position 111 (p.T111I) which maps to the G-H loop at the high-affinity 
Eph/ephrin interface (Nikolov et al. 2005). To determine the role of these missense 
mutations in EphB2/ephrin-B1 signalling and cell behaviour, a cell culture model was 
established. Expression constructs containing wild type, c.161C>T/(p.P54L) and 
c.332CC>TA/(p.T111I) EFNB1 cDNA, respectively, were generated by site-directed 
mutagenesis and used for transfection of NIH 3T3 cells (Fig. 7a). NIH 3T3 were 
chosen while they do not express mouse homologues of B-type ephrin genes 
(Moreno-Flores et al. 2002 and our results, Fig. 7b, first well). Transfection efficiency 
of the constructs in NIH3T3 was monitored by RT-PCR and FACS analysis (Fig. 7b, 
c). 
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3.2.2. The role of p.P54L and p.T111I mutations in cell behaviour: patches 
formation analysis 
 
It is known, that the EphB2/ephrin-B1 system is important for the cell behaviour, 
adhesion and repulsion (Klein et al. 2004). The role of EphB2 expressing cells in 
these processes has been intensively investigated (Stein et al. 1998; Zimmer et al. 
2003). The role of ephrin-B1 expressing cells, however, appears to be less clear. To 
understand the impact of missense mutations on cell behaviour, wild type, p.P54L 
and p.T111I ephrin-B1 expressing NIH3T3 cells were stimulated with preclustered 
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Fig. 7 Generation of c.161C>T and c.332CC>TA EFNB1 cDNA constructs by site-directed 
mutagenesis and transfection into NIH 3T3. a Sequence analysis of the EFNB1 cDNA constructs 
(exon 2) after the site-directed mutagenesis. The upper panel for each mutation represents the result 
of the mutagenesis while the lower panel represents the wild type EFNB1 cDNA. Nucleotide 
exchanges are indicated by arrow and bracket. b RT-PCR using EFNB1 specific primers was 
performed. RT-PCR products of the primary NIH 3T3 cells (lane 1), NIH 3T3 cells tranfected with wild 
type, c.161C>T (p.P54L), c.332 CC>TA (p.T111I) EFNB1 cDNA constructs, respectively (lanes 2-6) 
and Cos-1 cells (lane 7). Size markers are shown in lane M (100 bp DNA ladder, Invitrogen) c FACS 
analysis of the NIH 3T3 cells transfection efficiency. Grey peaks show maximum of GFP 
fluorescence in NIH 3T3 transfected cells. Empty peaks show maximum of GFP fluorescence in
untransfected control cells. 
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EphB2-Fc for 30 min. After the stimulation cells were cultivated for 24 h and than 
pictures of the cells were taken using the fluorescence microscopy method. Pictures 
showed that wild type and p.T111I ephrin-B1 expressing NIH3T3 cells formed 
clusters (Fig. 8a), whereas cells expressing p.P54L ephrin-B1 were scattered much 
like the ephrin-B1 expressing cells in the control following Fc-only treatment (Fig. 8a) 
or like the ephrin-B1 – expressing cells before the stimulation (not shown). 
wt 
p.P54L 
p.T111I 
a EphB2-Fc Fc 5’    10’    15‘   20’   25’   30’
wt + Fc 
wt + 
EphB2-Fc 
p.P54L + 
EphB2-Fc 
p.T111I + 
EphB2-Fc 
anti-ephrin-B1
antibody 
b 
anti-phospho-ephrin-B1 
antibody 
5’    10’    15’  20’   25’   30’
Fig. 8 EphB2-Fc stimulation of wild type, p.P54L, p.T111I ephrin-B1 expressing NIH 3T3 cells. a
Right panel: NIH 3T3 cells expressing wild type and p.T111I eprin-B1 were detected by
fluorescent microscopy as cell clusters after the EphB2-Fc stimulation (indicated by arrows). No
patches was detected in the p.P54L expressing cells. Left panel: the same cell lines treated with
Fcwere, cells do not form any patches. b Western blot analysis of the wild type, p.P54L and
p.T111I ephrin-B1 expressing NIH 3T3 cells. Cells were stimulated for 5 to 30 min with EphB2-Fc,
proteins were extracted. Western blot was performed using the Phospho-Ephrin B (Tyr324/329)
antibody and anti-ephrin-B1 antibody. NIH 3T3 cells transfected with wild type ephrin-B1 and
treated with Fc were used as a control. Protein sizes were determined using Precision Plus
ProteinTM Standards Dual Color (BIO-RAD). 
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3.2.3. The role of p.P54L and p.T111I mutations in ephrin-B1 phosphorylation 
 
Reverse signalling of ephrin-B1 involves phosphorylation of several conserved 
tyrosine residues of the cytoplasmic tail, including Tyr324 and Tyr329 (Kalo et al. 
2001). To determine the impact of c.161C>T and c.332C>T missense mutations on 
this Tyr-phosphorylation, the timing Tyr324 and Tyr329 of wild type and mutant 
ephrin-B1 was investigated. NIH 3T3 cells expressing c.161C>T and c.332C>T 
EFNB1 were stimulated with preclustered EphB2-Fc from 5 to 30 min. After the 
stimulation, Tyr324 and Tyr329 phosphorylation response was monitored by Western 
blot analysis using Tyr324/329-specific polyclonal antibodies (Fig. 8b). 
Phosphorylation status was checked after 5, 10, 15, 20, 25 and 30 minutes of 
stimulation. This showed phosphorylation of the wild type ephrin-B1 began to be 
detectable approximately at 15th min after the stimulation and prolonged to at least 
30th minute. In p.T111I mutant ephrin-B1 expressing NIH3T3 cells, phosphorylation 
appeared to be detectable approximately at 20th minute of stimulation and prolonged 
for a shorter period of time, approximately until 25th minute of stimulation. For p.P54L 
mutant ephrin-B1 no phosphorylation was detected like in the control wild type 
ephrin-B1 expressing cells treated with Fc only. 
 
3.3. Expression analysis of Msx2 and Twist1 genes 
 
After the analysis of wild type and mutant ephrin-B1 phosphorylation, it was 
decided to have a look at the other members of ephrin-B1 reverse signalling. 
It was proposed that ephrin-B1 stimulation with EphB2-Fc would change the 
expression level of Msx2 and Twist1 genes via ephrin-B1 – Stat3 interaction. To 
measure the expression level of genes, a real-time PCR analysis was performed. 
Cells expressing wild type, p.P54L and p.T111I ephrin-B1 were stimulated with 
EphB2-Fc for 30 min. After the stimulation NIH 3T3 fibroblasts were harvested for the 
RNA extraction. This RNA was reverse transcribed into the cDNA that was used for 
the real-time PCR. To calculate the relative Msx2 and Twist1 expression, a 
housekeeping gene G3PDH was used as a control to exclude the mistakes caused 
by natural expression variation between the cell lines. In this experiment only the 
expression change exceeding the 2 fold was used as a relevant change. This was 
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done to exclude the possible mistakes caused by minor variations of transfection rate 
and pipetting. 
It was already known that p.P54L rather had loss-of-function effect. No change 
either of Twist1 or Msx2 expression level was expected and only the minor, not 
exceeding the 2 fold was detected. Also, only the minor Twist1/Msx2 expression level 
change was detected in p.T111I expressing sells. Surprisingly, also no exceeding the 
2 fold changes in expression level of genes of interest was detected in cells 
transfected with wild-type ephrin-B1 (Fig. 9). 
Cut-off of the fold difference less than 2 was chosen according to the 2-Δ(ΔCt) 
formula. Such cut-off means that the minimal difference between the threshold cycles 
of the genes of interest must be at least 1 cycle. The cut-off helps to avoid the 
pipetting and instrumental mistakes. 
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Fig. 9 Real-time PCR analysis of
Twist1 and Msx2 in ephrin-B1
expressing NIH 3T3 cells. Cells were
transfected and stimulated with EphB2-
Fc for 30 min as it is described before.
Stimulated cells were used for the RNA
extraction, RNA was reversed
transcribed to cDNA and used for the
real-time PCR. As it was expected, no
change of Twist1 and Msx2 expression
level was detected in p.P54L. No
change of Twist1 and Msx2 expression
level was detected in p.T111I.
Surprisingly, no change of Twist1 and
Msx2 expression level was detected in
wild type ephrin-B1 expressing cells. 
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4. Discussion 
 
4.1. PTC-causing mutations 
 
4.1.1. Frameshift mutation c.377_384delTCAAGAAG 
 
In this study, we examined the impact of disease-causing mutations in the EFNB1 
gene. 
Frameshift mutation c.377_384delTCAAGAAG was described in a patient with 
classical CFNS. This mutation is located in exon 2 and leads to numerous PTCs, first 
of them appears 17 nucleotides upstream the 3’-end of exon 2 (Wieland et al., 2008). 
Subcloning of the patient fibroblasts primary culture and HUMARA of the subclones 
showed that two populations of cells with the different active alleles of EFNB1 exist 
and can be separated in vitro. Carrel and Willard (2005) have shown that 
approximately 15% of the X-chromosome located genes escape the X-linked 
inactivation. Inactivation of EFNB1 was shown to depend from the X-chromosome 
inactivation pattern. Expression analysis of the patient fibroblasts showed the strong 
decrease of the mutant EFNB1 allele expression level, probably, due to NMD. 
According to that, c.377_384delTCAAGAAG mutation rather had loss-of-function 
effect. 
Previously, it has been shown in silico and in vitro that CFNS causing mutations 
disrupt or alter the ephrin-B1 function (Nikolov et al. 2005). The major types of 
mutations include frameshift, nonsense and splice site mutations that generate 
premature termination codons. PTC containing mRNA could give rise to truncated, 
soluble ephrin-B1 polypeptides that lack the transmembrane and intracellular 
domains. These soluble peptides could be secreted from the mutant EFNB1 
expressing cells and could interact with EphB-receptors expressing cells located far 
from the EFNB1 expressing cells altering and disrupting the EphB-receptor forward 
signalling. Truncated ephrin-B1 polypeptides could exhibit dominant-negative or gain-
of function effects. 
However, usually PTCs lead to nonsense-mediated mRNA decay. NMD generally 
involves nonsense codon recognition by translating ribosomes at a position ≈25 
nucleotides upstream of a splicing-generated exon junction complex of proteins. As 
such, NMD provides a means to degrade abnormal mRNAs that encode potentially 
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deleterious truncated proteins. Additionally, an estimated one third of naturally 
occurring, alternatively spliced mRNAs is also targeted for NMD (Hillman et al., 2004; 
Lewis et al., 2003; Mendell et al., 2004). Given the extraordinary frequency of 
alternative splicing together with data indicating that naturally occurring transcripts 
other than alternatively spliced mRNAs are likewise targeted for NMD, it is expected 
that mammalian cells routinely utilize NMD to achieve proper levels of gene 
expression (Lejeune and Maquat, 2005). In mammalian cells NMD generally occurs 
when a nonsense codon resides >50–55 nucleotides upstream of a splicing-
generated exon-exon junction and is followed by at least one intron (Nagy and 
Maquat, 1998). Also, it was shown that some genes such as natural intronless genes 
mouse histone H2a and human histone H4 are resistant to NMD (Maquat and Li, 
2001). NMD also was described to play a role in cancer development (Culbertson, 
1999). Chain-termination mutations that reduce mRNA abundance by reducing the 
half-life of mRNA typically behave like loss-of-function alleles. For example, a 
recessive form of β-thalassemia (OMIM 141900) common in Mediterranean 
populations results from a mutation that generates a premature UAG stop codon in 
the HBB gene (OMIM 141900). This leads to severely reduced haemoglobin-β mRNA 
accumulation (Baserga and Benz, 1992). 
 
4.1.2. Frameshift mutation c.614_615delCT and splice-site mutation c.406+2T>C 
 
Frameshift mutation c.614_615delCT has been previously described in a sporadic 
female patient with CFNS including coronal craniosynostosis, duplex kidneys and 
diaphragmatic hernia (Wieland et al. 2008). This di-nucleotide deletion occurred in 
exon 4 of EFNB1 and generates a PTC in 14 nucleotide upstream of 3’-end of the 
exon 4. This mutation escapes the NMD according to the “55” bp rule. Expression 
analysis of patient fibroblasts revealed transcripts from mutant and wild type alleles at 
similar amounts, whereas only the wild type but no truncated ephrin-B1 was detected 
by Western blot analysis. This rather suggests that truncated ephrin-B1 proteins are 
instable and do not contribute substantially to the CFNS phenotype. In this case 
mutant and wild type EFNB1 transcripts presented at similar amounts but 
nevertheless amount of the mutant protein was drastically decreased and the 
c.614_615delCT seemed to have a loss-of-function effect. 
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In another female patient with classical CFNS phenotype, splice site mutation 
c.406+2T>C was detected. Mutations at this splice donor site have been recently 
described in two independent families (Wallis et al. 2008). In the patient examined 
here c.406+2T>C occurred de novo. In general, splice site mutations constitute about 
10% of CFNS point mutations, which is within the range observed in other human 
genetic diseases (Krawczak et al. 1992). Expression analysis of the patient’s 
fibroblasts revealed retention of intron 2 as has been previously detected for the 
splice acceptor “AG” mutation c.407-2A>T at the same exon junction (Wieland et al. 
2008). In addition, activation of a cryptic splice site in the preceding exon 2 was 
detected for c.406+2T>C, apparently a frequent consequence of 5’ splice site 
mutations (Buratti et al. 2007; Krawczak et al. 1992). Both, intron retention and 
cryptic splice site activation resulted in PTCs and reduced transcript amounts when 
compared with the wild type allele. Like in case of c.614_615delCT mutation, no 
truncated soluble ephrin-B1 polypeptide was detected in native patient fibroblasts. 
As it was already mentioned, mutation c.377_384delTCAAGAAG leads to the 
strong reduction of the mutant EFNB1 transcription level probably due to NMD. 
However, some chain-termination mutations confer a dominant phenotype when the 
RNA-surveillance system is bypassed. The most clearly defined bypass mechanism 
involves the skipping of constitutively spliced exons. For example, exon skipping 
associated with a nonsense mutation has been documented the FBN1 (fibrillin) gene 
(OMIM 134797) causing Marfan syndrome (OMIM 154700, Dietz and Kendzior, 
1994). Nonsense-associated exon skipping probably occurs when a nonsense 
mutation is fortuitously located at a position that affects splice-site selection through 
changes in RNA structure. 
Frameshift mutation c.614_615delCT and splice site mutation c.406+2T>C, both, 
were predicted to result in protein truncation preceding the transmembrane domain of 
ephrin-B1. This stimulated us to investigate whether the observed mutant transcripts 
will give rise to a truncated soluble ephrin-B1 protein product. Such protein may 
exhibit dominant-negative or gain-of-functions effects. To determine, whether mutant 
transcripts give rise to a truncated ephrin-B1 protein, Western blot analysis was 
performed. In contrast to presence of wild type and mutant RNA transcripts in patient 
fibroblasts, only wild type but not a mutant truncated ephrin-B1 protein was detected 
in both c.614_615delCT and c.406+2C>T fibroblast cultures. It was proposed, that 
truncated ephrin-B1 is rapidly degraded in the patient fibroblasts. We proposed that 
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the protein was synthesized and degraded rather than not synthesized because it is 
known, that rapid degradation of newly synthesized proteins is a routine process. It 
was shown, that up to 30 % of all newly synthesized proteins are defective and were 
degraded immediately after the synthesis (Schubert et al., 2000). 
Absence of the mutant protein shows that mutations c.614_615delCT and 
c.406+2C>T appear to have a loss-of-function effect. Frameshift mutation 
c.377_384delTCAAGAAG also seems to have loss-of-function effect. According to 
our results and previously published data, we conclude that the major part of all PTC-
causing mutations has neither dominant-negative, nor gain-of-function effects but 
rather loss of function effect. 
Plenty of dominant-negative mutations of different genes are known up to now. 
One of these genes is SOX10 (OMIM 602229). This gene encodes the transcription 
factor SOX10. It was shown by Kuhlbrodt et al. (1998) and Pingault et al. (1998) that 
mutations of this gene cause Waardenburg-Shah syndrome (WS4, OMIM 277580). 
Several dominant-negative mutations of this gene have been described including the 
protein-truncating mutations (Sham et al., 2001). This mutation cause more severe 
disease manifestation than loss-of-function mutations. 
Why in case of SOX10 the truncated protein exists and causes a dominant-
negative effect while ephrin-B1 truncated protein is rapidly degraded? It is known that 
C-terminal part of ephrin-B1 plays an important role in the glycosylation and 
transporting of the protein to the Golgi apparatus and further to the membranes 
(Compagni et al. 2003; Davy et al. 2004, 2006). In contrast, C-terminal part of SOX10 
does not have any point that can be crucial for the protein transporting. 
 
4.2. Missense mutations p.P54L and p.T111I 
 
Mutation c.161C>T/p.P54L was found in a family with the mother and a daughter 
affected by craniofrontonasal syndrome and the maternal hemizygous grandfather 
(Wieland et al., 2004). The grandfather showed only slight facial asymmetry and a 
broad nasal bridge. His daughter showed severe facial asymmetry, hypertelorism, 
and hypoplasia of the corpus callosum. The granddaughter exhibited facial 
asymmetry, hypertelorism, agenesis of the corpus callosum, complete syndactyly of 
the third and fourth finger on the left side, and scoliosis. This mutation was also 
described by Twigg et al. (2006) in a familiar case with a mosaicism in the mother of 
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affected son and daughter. The female proband had classical CFNS and her brother 
had hypertelorism and a nasal pit, but their mother did not show any CFNS features 
apart from slight nasal asymmetry and longitudinal grooves in her nails. Wieland et 
al. (2005) described this mutation in a sporadic case. 
Mutation c.332C>T/p.T111I was found in six affected females and three male 
carriers of a family over five generations (Wieland et al., 2004). The phenotypes of 
the female patients included hypertelorism, orbital asymmetry, brachycephaly, 
brachydactyly, and Sprengel deformity. One affected female experienced four 
miscarriages in midpregnancy and was found to have an uterus arcuatus. In addition 
she had curly hair, grooved fingernails, and unilateral breast hypoplasia. 
Missense mutation p.P54L presumably leads to a conformational change of the 
extracellular ephrin domain and p.T111I specifically alters the G-H loop involved in 
Eph receptor - ephrin-B1 recognition (Nikolov et al. 2005). Since c.161C>T mutants 
is located at the border between B and H β-strands of the extracellular domain, it is 
unlikely to result in unstable protein (Mellitzer and Wilkinson, 1999; Wieland et al., 
2008). Rather, p.P54L mutation disturbs the ligand receptor clustering in cell–cell 
contacts. 
Missense mutation c.332C>T is also located in exon 2. It changes threonine for 
isoleucine at ephrin-B1 position 111 (p.T111I) which maps to the G-H loop at the 
high-affinity Eph/ephrin interface (Nikolov et al. 2005). Both missense mutations 
replace amino acid residues are highly conserved in the three human ephrin-B 
ligands and across a great variety of species, they were predicted to compromise the 
biological activity of ephrin-B1 (Nikolov et al. 2005; Wieland et al. 2004). 
It has been shown previously, that upon Eph receptor – ephrin-B1 interaction, 
reverse signalling proceeds through phosphorylation of six tyrosine residues 
(corresponding to human Tyr313, Tyr317, Tyr324, Tyr329, Tyr343 and Tyr344) in the 
intracellular part of ephrin-B1 (Chong et al. 2000). Addition of recombinant 
extracellular domain of EphB2 to ephrin-expressing cells in tissue culture similarly 
caused tyrosine phosphorylation of the ephrin (Brückner et al. 1997; Holland et al. 
1996). Phosphorylation of Tyr 324 and 329 by Src kinases was shown to be the most 
important for ephrin-B1 reverse signalling (Kalo et al. 2001; Lee et al. 2008; Tanaka 
et al. 2005). Western blot analysis was performed to detect phosphorylation of 
Tyr324 and Tyr329 of wild type, p.P45L and p.T111I proteins in response to EphB2-
Fc receptor stimulation. For p.P54L mutant ephrin-B1 no phosphorylation was 
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detected. In contrast, p.T111I ephrin-B1 still showed Tyr324/329 phosphorylation like 
the wild type protein, although the timing appeared slightly different. Since p.T111I 
undoubtedly causes the CFNS phenotype, phosphorylation of Tyr324/329 may be 
less important for disease manifestation. 
Reverse signalling influences actin cytoskeletal rearrangement and may result in 
transcriptional regulation of different genes involved in extracellular matrix 
reorganization (Campbell et al. 2008; Cowan and Henkemeyer 2001). NIH3T3 cells 
expressing either wild type or mutant ephrin-B1 exhibited differences in patches 
formation after EphB2-Fc stimulation. Cells expressing wild type or mutant ephrin-B1 
were visualized by the green fluorescent protein and showed a scattered distribution 
in tissue culture dishes before stimulation. EphB2-Fc stimulation induced formation of 
patches in the wild type and p.T111I protein expressing cells, whereas no cell 
patches were found in p.P54L expressing cells. This suggests that phosphorylation of 
Tyr324/329 is closely linked with the patches formation, however, the mechanism of 
this linkage is unclear. Possible reasons are that wild type and p.T111I expressing 
cells experience a proliferative signal upon EphB2 stimulation. After division daughter 
cells do not move apart but rather stay close together. Alternatively, cells respond to 
EphB2 stimulation with increased motility and migrate into clusters. For ephrin-B2 it 
has been shown in the mouse that restriction of cell intermingling and communication 
was dependent on bi-directional signalling, whereas unidirectional activation of 
ephrin-B2 by recombinant truncated EphB2 was sufficient to restrict cell-cell 
communication through gap junctions (Mellitzer et al. 1999). Similar observations 
have been reported for ephrin-B1 by Davy et al. (2006) who proposed that regulation 
of gap junctions contributes to cell sorting downstream of Eph – ephrin interaction. In 
addition, embryonic mouse cells expressing an ephrin-B1 lacking the most C-terminal 
PDZ binding domain do not sort-out from wild type cells, whereas ephrin-B1 null cells 
do (Compagni et al. 2003; Davy et al. 2004, 2006). In this respect, it is striking that 
CFNS-causing missense mutations have been detected exclusively in the exons 
encoding the extracellular region of ephrin-B1, which strongly argues for the 
involvement of Eph receptor forward signalling in the pathogenic mechanism. We 
propose that CFNS is caused mostly by disturbance of Eph receptor forward 
signalling and the consequences of cellular interference in heterozygous females. 
What is the role of ephrin-B1 expressing cells? After EphB/ephrin-B1 system 
activation EphB expressing cells begin to repulse (Mellitzer et al., 1999). We 
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proposed that ephrin-B1 cells stop their moving and attach themselves to the surface. 
This hypothesis is proven by patches formation analysis. Salvucci et al. (2006) have 
described an influence of ephrin-B1 on CXCR4 signalling in T-cells. This protein is 
important for cell migrations such as T-cells’ homing (Busillo and Benovic, 2007). 
Ephrin-B1 activates PDZ-RGS3 that downregulates the CXCR4 activation preventing 
chemotaxis of the T-cells (Sharfe et al., 2002). 
As it was told before, we assume that the major part of all PTC-causing mutations 
has neither dominant-negative, nor gain-of-function effects but rather loss of function 
effect. In this part of work we found out that p.P54L mutations also seemed to have a 
loss-of-function effect. According to our results and previously published data, we 
assume that the majority of disease-linked EFNB1 mutations cause loss-of-function 
effect. 
Analysis of the other Tyr residues (Tyr313, Tyr317, Tyr343 and Tyr344) 
phosphorylation may show whether p.P54L lacks the phosphorylation completely or 
in this case only the phosphorylation of Tyr324 and Tyr329 is disturbed. Analysis of 
the Tyr phosphorylation in wild type and p.T111I would reveal the crucial for the 
CFNS manifestation Tyr residues. 
It is known that ephrin-B1 needs several other proteins such as Grb4 and Src 
kinases for the reverse signalling. These proteins form a complex with ephrin-B1 after 
it binds EphB2. It would be interesting to analyse the formation of this complex with 
the p.P54L and p.T111I ephrin-B1. 
 
4.3. Real-time PCR 
 
As it was said before, Bong et al. (2007) reported that Tyr329 is important for the 
ephrin-B1 – STAT3 complex formation. Hence, we expect disturbance of STAT3 
signalling in p.P54L expressing cells. Stat3 is an important transcription factor, e.g. it 
controls expression of Twist1 (Cheng et al., 2008) and mutations of Twist1 gene are 
involved in craniosynostosis formation (Merrill et al., 2006). It is also known that Msx2 
works together with Twist1 in coronal suture formation. 
The pathway of the ephrin-B1 reverse signalling is not clear till now. But it is 
known that EFNB1 mutation may lead to the craniosynostosis formation. That is why 
we tried to find a link between ephrin-B1 pathway and STAT3 pathway. 
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Twist1 and Msx2 expression experiments were performed in primary fibroblasts 
(not shown) and in transfected NIH 3T3 cells. In both cases real-time PCR did not 
indicate a change in the expression levels of these genes exceeding the 2 fold. While 
expression level of Twist1 and Msx2 do not change in response to ephrin-B1 
stimulation, it is proposed that the Stat3 signalling involves some other proteins. In 
this case, there are other genes that are involved in ephrin-B1 reverse signalling. To 
answer this question, other genes from the Twist1 pathway need to be analysed. 
Also it would be interesting to investigate pathways of the growth factors and 
cytokines related to neural stem cells. 
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Conclusions 
 
1. In this work three PTC-causing mutations were analysed: frameshift 
c.377_384delTCAAGAAG, splice-site c.406+2T>C and deletion 614_615delCT. One 
mutation (c.377_384delTCAAGAAG) was shown to express no mutant transcript. 
Two other mutations give rise to the mutant RNA, but no mutant protein was 
detected. According to these results and previously published data, it can be 
concluded, that the majority of PTC-causing EFNB1 mutations have neither 
dominant-negative, nor gain-of-function effects but rather loss of function effect. 
 
2. The analysis of missense mutations c.161C>T/p.P54L and 
332_333CC>TA/p.T111I revealed that both cause CFNS but have different 
mechanisms of ephrin-B1 signalling disturbance. Mutation p.P54L seems to have 
loss-of-function effect (no Tyr324/329 phosphorylation of the p.P54L ephrin-B1 and 
no patches formation of the p.P54L expressing cells were shown), whereas p.T111I 
ephrin-B1 differs slightly from the wild type in phosphorylation timing, and p.T111I-
expressing cells show patches formation. Therefore, additional mechanisms involved 
in phenotypic manifestation need to be postulated. This may include either other 
tyrosine residues of ephrin-B1 are more important for reverse signalling. Another 
possibility could be impaired forward signalling of Eph receptor expressing cells. 
Combined with cellular interference this may be the main pathogenic mechanism in 
CFNS manifestation in female patients. 
 
3. Expression of Twist1 and Msx2 genes was analysed in response to ephrin-B1 
stimulation. Only the minor changes of the Twist1 and Msx2 expression level were 
found after the ephrin-B1 stimulation in wild type and in mutant ephrin-B1 expressing 
cells. From this we may conclude that Twist1 and Msx2 are not the main targets of 
the ephrin-B1 mediated STAT3 signalling. 
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Summary (English) 
Ephrin-B1 protein forms signalling complexes with EphB receptor expressed in 
complementary cells. This complex was shown to work as a bi-directional signalling 
system, and ephrin-B1 was called “receptor-like protein”. Ephrin-B1 is encoded by 
EFNB1 gene. Mutations of this gene cause the X-linked disease called 
craniofrontonasal syndrome (CFNS). This disease shows an unusual phenotypic 
pattern of inheritance, it affects heterozygous females more severely than 
hemizygous males although EFNB1 is located on the X chromosome and has no 
homologue on the Y chromosome. This inheritance has been explained by random 
X-inactivation in heterozygous females and the consequences of cellular interference 
of wild type and mutant EFNB1-expressing cell populations with EphB-receptors 
expressing cells. Several patient derived EFNB1 mutations have been analysed in 
this work, which consists of two parts. First one premature termination codon (PTC)-
causing mutations were analysed: frameshift mutation c.377_384delTCAAGAAG, 
frameshift mutation c.614_615delCT (PTC in exon 4) and splice-site mutation 
c.406+2T>C (PTC in intron 2 or exon 3). All three mutations were predicted in silico 
to result in a truncated, soluble ephrin-B1 protein. Such protein would cause distant 
interaction with EphB-receptors. In the second part of this work the impact of 
missense mutations c.161C>T/p.P54L and c.332C>T/p.T111I on cell behaviour and 
reverse ephrin-B1 cell signalling was investigated. The role of these mutations was 
analysed in a cell culture model using NIH3T3 fibroblasts. This cell line was chosen 
because it does not express Efnb1, the mouse homologue of EFNB1 gene. Both 
missense mutations are located in the extracellular ephrin domain that is involved in 
Eph-ephrin-B1 recognition and higher order complex formation. Reverse signalling of 
ephrin-B1 involves phosphorylation of several conserved tyrosine residues of the 
cytoplasmic tail. Two of them, Tyr324 and Tyr329 in human ephrin-B1, were shown 
to be the most important for signal transduction. To analyse the impact of missense 
mutations in ephrin-B1 signalling the phosphorylation of these two amino acids in 
mutant and wild type ephrin-B1 was monitored after the EphB2-Fc stimulation. It was 
reported previously, that ephrin-B1 is involved in STAT3 signalling pathway. Also, it is 
known that STAT3 controls the expression of TWIST1 gene and MSX2 is also 
involved in STAT3 signalling. According to that, the change of expression level of 
MSX2 and TWIST1 due to ephrin-B1 stimulation was monitored. 
Mutation c. .377_384delTCAAGAAG showed a strong decrease of the mutant 
transcript level, mutations c.614_615delCT and c.406+2T>C showed the presence of 
the mutant RNA but not the mutant protein. 
Mutation p.P54L showed no phosphorylation of the Tyr324/329, wild type and 
p.T111I mutation showed the difference in the phosphorylation timing. Also wild type 
and p.T111I expressing cells showed patches formation after the EphB2-Fc 
stimulation whereas p.P54L expressing cells remained to be scattered. 
MSX2 and TWIST1 genes showed only a minor change of the transcription level in 
response to the ephrin-B1 stimulation with EphB2. 
Four from the five investigated EFMB1 mutations appeared to have rather loss-of-
function. 
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Zusammenfassung (Deutsch) 
 
Das Protein Ephrin-B1 bildet einen Signalkomplex mit dem EphB-Rezeptor, der in 
komplementären Zellen exprimiert wird. Es wurde gezeigt, dass dieser Komplex als 
ein bidirektionales Signalsystem funktioniert und deswegen wurde Ephrin-B1 als 
Rezeptor-ähnliches Protein benannt. Ephrin-B1 wird vom EFNB1 Gen kodiert. 
Mutationen des EFNB1-Gens verursachen eine X-chromosomale Erkrankung – das 
Craniofrontonasale Syndrom (CFNS). Diese Erkrankung zeigt ein ungewöhnliches 
Vererbungsmuster: heterozygote Frauen weisen das Vollbild der Erkrankung auf, 
während hemizygote Männer keine oder nur eine leichte Symptomatik zeigen, 
obwohl das EFNB1 Gen auf dem X-Chromosom lokalisiert ist und kein homologes 
Gen auf dem Y-Chromosom hat. Dieses Vererbungsmuster wurde durch zufällige X-
Inaktivierung bei heterozygoten Frauen und als Folgen der zellulären Interferenz 
erklärt. Die zelluläre Interferenz entsteht durch Ergebnis von mutierten und 
Wildtypzellen mit EphB-Rezeptor expremierenden Zellen. In dieser Arbeit wurden 
einige EFNB1 Mutationen die bei Patienten identifiziert werden, untersucht. Die 
Arbeit besteht aus zwei Teilen. Der erste Teil beinhaltet die Analyse von drei 
Mutationen, die eine vorzeitige Termination (PTC, premature termination codon) 
verursachen: Leseraster Mutation c.614_615de1CT (PTC in Exon 4) und Spleiß-
Mutation c.406+2T>C (PTC in Intron 2 oder Exon 3). Es wurde vorhergesagt, dass 
die Anwesenheit jeder dieser Mutationen zur Bildung eine verkürzten, löslichen Form 
des Ephrin-B1 Proteins führt. Dieses verkürzte Protein könnte eine Blockierung des 
EphB-Rezeptors bewirken. Der zweite Teil der Arbeit beinhaltet die Untersuchung 
der Missense Mutationen c.161C>T/p.P54L und c.332C>T/p.T111I auf das 
Zellenverhalten und die Ephrin-B1 Signaltransduktion. Die Auswirkungen dieser 
Mutationen wurde im Zellkulturmodell unter Anwendung von NIH3T3 Fibroblasten 
analysiert. Diese Zelllinie wurde ausgewählt, weil sie kein Ephrin-B1 der Maus 
exprimiert. Beide Missense Mutationen sind in der extrazellulären Ephrin-Domäne 
lokalisiert. Diese Domäne kann zur Erkennung von Eph-Rezeptor und Ephrin-B1 und 
zur Bildung eines hoch-komplexen Multiproteins beitragen. Bei der Durchführung des 
reversen Ephrin-B1 Signals ist die Phosphorylation der bestimmtes evolutionär 
konservierten Tyrosin-Reste des zytoplasmatischen Anteiles notwendig. Es wurde 
gezeigt, dass die beiden Tyr324 und Tyr329 im menschlichen Ephrin-B1 Protein 
besonders wichtig für die Signaltransduktion sind. Um zu analysieren, welche Rolle 
Missense Mutationen bei der Ephrin-B1 Signaltransduktion spielen, untersuchte ich 
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die Phosphorylierung dieser zwei Aminosäuren bei Mutanten und Wildtyp Ephrin-B1 
nach der EphB2-Fc Stimulation. Frühere Ergebnisse zeigten, dass Ephrin-B1 Protein 
den STAT3 Signalwege aktiviert. Es ist auch bekannt, dass STAT3 die Expression 
des TWIST1 Gens kontrolliert und das MSX2 Gen in den STAT3 Signalwege 
integriert ist. Aus diesem Grund wurde Expression des MSX2 Gen und TWIST1 
Gens in Antwort auf die Ephrin-B1 Stimulation untersucht. Jedoch konnte keine 
Veränderung in der Expression dieses Gen festgestellt werden. 
Es wurde gezeigt: 
1. Mutation c.377_384delTCAAGAAG weist eine starke Reduzierung der 
Expression des mutant Allels auf. Mutationen c.614_615delCT und c.406+2T>C 
zeigten die Expression des mutant Allels, aber kein mutant Protein war zufinden. 
2. Mutation p.P54L weist keine Tyr324/329 Phosphorylation auf, Wildtyp und 
p.T111I Mutation demonstrierten nur geringe Differenzen zwischen den 
Phosphorylation Zeit. 
3. MSX2 und TWIST1 Gene zeigten geringe Differenzen in der Änderung der 
Expression in Antwort auf die Ephrin-B1 Stimulation. 
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